Long-term oral anticoagulant treatment after myocardial infarction : results of the 'Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis' (ASPECT) trial by Bergen, P.F.M.M. (Paul F. M.) van
Long-term oral anticoagulant treatment 
after myocardial infarction 
Results of the 'Anticoagulants in the Secondary Prevention 
of Events in Coronary Thrombosis' (ASPECT) trial 
CIP-DATA KONINKLIJKE BIBLIOTHEEK, DEN HAAG 
Bergen, Paul Ferdinand Maria Maurice van 
Long-term oral anticoagulant treatment after myocardial 
infarction : results of the' Anticoagulants in the 
Secondary Prevention of Events in Coronary Thrombosis' 
(ASPECT) trial/Paul Ferdinand Maria Maurice van Bergen. 
- [S.1. : s.n.]. - Ill. 
Thesis Rotterdam. - With ref. - With summary in Dutch. 
ISBN 90-9007744-8 
NUGI 746 
Subject headings: anticoagulants; myocardial infarction 
Cover design: S. Oei 
Copyright: Paul F.M.M. van Bergen. No part of this publication may be 
reproduced, stored in a retrieval system, or transmitted, in any form or by any 
means, electronic, mechanical, photocopying, recording or otherwise, without the 
prior permission of the author. 
"VPrinted by: Haveka B. V., Alblasserdam, The Netherlands. 
Long-term oral anticoagulant treatment 
after myocardial infarction 
Results of the' Anticoagulants in the Secondary Prevention 
of Events in Coronary Thrombosis' (ASPECT) trial 
Langdurige orale antistollingsbehandeling 
na een myocardinfarct 
Resultaten van het 'Anticoagulants in the Secondary 
Prevention of Events in Coronary Thrombosis' (ASPECT) onderzoek 
PROEFSCHRIFT 
ter verkrijging van de graad van doctor 
aan de Erasmus Universiteit Rotterdam 
op gezag van de rector magnificus 
Prof. Dr P.W.C. Akkermans, M.A. 
en volgens besluit van het college voor promoties. 
De openbare verdediging zal plaatsvinden op 
woensdag 23 november 1994 OIll 15.45 uur 
door 
Paul Ferdinand Maria Manrice van Bergen 
geboren te Breda 
PROMOTIECOMMISSIE 
Promotores: 
Copromotor: 
Overige leden: 
Prof. Dr A. Hofman 
Prof. Dr F.W.A. Verheugt 
Dr J.W. Deckers 
Prof. Dr M.L. Simoons 
Prof.Dr T.W. Meade 
Aall Annette, Alldrea ell los 
Acknowledgements 
The author gratefully acknowledges the collaboration with the members of the 
Steering Committee, the Policy Board, the Data Monitoring Committee and the 
Mortality and Morbidity Classification Committee of the ASPECT trial; the 
cardiologists and the staff of the participating hospitals; the employees of the 
thrombosis centres; the pharmacists in charge of the trial medication; 
the Federation of Dutch Thrombosis Centres; the members of the computer groups 
of the Thoraxcentre Rotterdam, TROmS and TDAS; the ROMERES Foundation 
and the staff of the ASPECT coordinating centre. 
The ASPECT trial was supported by a main grant of the Praeventiefonds (28-978). 
Additional support was obtained from the Netherlands Thrombosis Foundation. 
We are indebted to Ciba-Geigy B.V. and Rodie Nederland B.V., the Netherlands 
for supplying the trial medication and Nycomed B.V., the Netherlands for 
additional funds. Roche Nederland B. V. and Nycomed B.V. also supported 
publication of this thesis. 
Financial support by the Netherlands Heart Foundation and the Rotterdam Medical 
Research Foundation (ROMERES) for the publication of this thesis is gratefully 
acknowledged. 
Contents 
Chapter 1 
Introduction 11 
Chapter 2 
Effect of long-term oral anticoagulant treatment on 
mortality and cardiovascular morbidity after myocardial 
infarction 19 
Chapter 3 
Efficacy of long-term anticoagulant therapy in 
subgroups of post myocardial infarction patients 39 
Chapter 4 
Cumulative meta-analysis of long-term anticoagulant therapy 
after myocardial infarction 59 
Chapter 5 
Characteristics and prognosis of non-participants of a 
multi-centre trial of long-term anticoagulant therapy 
after myocardial infarction 81 
Chapter 6 
Costs and effects of long-term oral anticoagulant treatment 
after myocardial infarction 97 
Chapter 7 
General discussion 113 
Chapter 8 
Summary 121 
Samenvatting 
Dankwoord 127 
Curriculum vitae 130 
Publications and manuscripts based on the studies described in 
this thesis 
Chapter 2 
The Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis 
(ASPECT) Research group. Effect of long-term oral anticoagulant treatment on 
mortality and cardiovascular morbidity after myocardial infarction. 
Lancet 1994; 343:499-503. 
Chapter 3 
P.F.M.M. van Bergen, J.W. Deckers, LJ.C. Jonker, R.T. van Domburg, A.J. 
Azar, A. Hofman. Efficacy of long-term anticoagulant treatment in subgroups of 
post myocardial infarction patients. 
British Heart Journal, ill press. 
Chapter 4 
P.F.M.M. van Bergen, J.J.C. Jonker, J.W. Deckers, F.W.A. Verheugt, A. 
Hofman. Cumulative meta-analysis of long-term anticoagulant therapy after 
myocardial infarction. 
Submitted. 
Chapter 5 
P.F.M.M. van Bergen, J.J.C. Jonker, G.P. Molhoek, P.R. van der Burgh, R.T. 
van Domburg, J.W. Deckers, A. Hofman. Characteristics and prognosis of non-
participants of a multi-centre trial of long-term anticoagulant treatment after 
myocardial infarction. 
Submitted. 
Chapter 6 
P.F.M.M. van Bergen, J.J.C. Jonker, B.A. van Hout, R.T. van Domburg, J.W. 
Deckers, A. Hofman. Costs and effects of long-term oral anticoagulant treatment 
after myocardial infarction. 
Journal of the American Medical Associatioll, ill press. 

Chapter 1 
Rationale for long-term anticoagulant therapy 
after myocardial infarction 
Chapter 1 
Introdnction 
Atherosclerosis 
Despite the fact that mortality from cardiovascular diseases has declined consi-
derably over the last decades, it still represents the leading cause of mortality and 
morbidity in industrialized countries.'·2 Most clinical manifestations of cardiovas-
cular disease share the underlying pathophysiological process of atherosclerosis. 
Atherosclerosis is a diseased state of the intima and media of medium to large sized 
arteries characterized by focal plaques preferentially located in areas of low shear. 
It is assumed that plaques origin from fatty streaks that are initiated by oxidation of 
low density lipoprotein. 3 Formation of fatty streaks may also follow initial injury 
from a wide range of agents including toxins, viral infections and intraluminal 
devices such as catheters. The subsequent inflammatory reactions induce smooth 
muscle proliferation by growth factor production from a wide range of cells 
including platelets, endothelial cells, macrophages, and other smooth muscle cells. 
The development of fatty streaks may already commence early in childhood and 
progress over a period of decades to become atherosclerotic plaques which contain 
lipid-filled foam cells, extracellular lipid and a layer of smooth muscle cells just 
beneath the endothelium.' Plaque growth is mediated by the proliferation of smooth 
muscle cells and extracellular connective tissue elements such as collagen, elastin, 
and proteoglycans. Growth factors derived from the interaction between platelets 
and the underlying artery wall further stimulates this process.'·6 This process will 
lead to the formation of a fibrolipid plaque that constitutes a core of extracellular 
lipid separated from the media by smooth muscle cells and covered and separated 
from the lumen by a thick cap of collagen-rich fibrous tissue containing smooth 
muscle cells. Surrounding the lipid core are lipid-filled foam cells. Elevated 
coronary plaques may cause clinical symptoms when the plaque size is sufficient to 
obstruct the normal bloodflow, usually when it occupies more than 40 percent of 
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the original cross-sectional area of the lumen. As the result of a dynamic interplay 
between plaque vulnerability, possibly mediated through a process of inflammation, 
and external stresses the atherosclerotic plaque surface may eventually rupture. 7•8 
Coagulation cascade and anticoaglliants 
Rupture of atherosclerotic plaques is followed by exposure of the de-endothelialised 
vessel wall to the blood and release of tissue factor. Subsequently, in addition to 
platelet deposition in the injured area, the clotting system is activated. Mediated 
through activation of clotting factors V, VII, IX and X, prothrombin (factor II) is 
transformed into thrombin. Thrombin is the most powerful activator of the 
coagulation system. Not only does thrombin activate platelets to expose the 
procoagulant lipids in their membrane and to release factor V, it also activates 
factor VIII and the receptor of the von Willebrandfactor, thus enhancing a positive 
feed-back loop producing huge amounts of thrombin. Also, fibrinogen is converted 
into fibrin monomers that spontaneously polymerise to form long fibrin strands. 
Subsequently, thrombin also activates factor XIII, which serves to crosslink the 
fibrin monomers to form an insoluble fibrin network with platelets which results in 
the formation of a fixed and occlusive platelet-fibrin thrombus.' 
Most of the various coagulant factors that are involved in the coagulation cascade 
are formed in the liver and transported in the blood. Factor VIII is formed 
elsewhere, probably in endothelial and lymphatic cells. Oral anticoagulants, usually 
consisting of coumarin derivatives, diminish the production of vitamin K dependent 
coagulation factors (factor II, VII, IX and X). Their close resemblance to vitamin 
K prevents the final, vitamin K dependent, carboxylation of the clotting factors II, 
VII, IX and X to become what are then called PIVKA's (Protein Induced by 
Vitamin K absence or Antagonist). IO By competition with the naturally available 
amount of vitamin K, coumarins influence the ratio of PIVKA's and coagulation 
factors. As PIVKA's are unable to catalyse the coagUlation cascade, the rate at 
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which prothrombin is activated decreases and the activation of thrombin and the 
subsequent formation of a thrombus are hampered. II 
Thrombosis alld myocardial ilifarctioll 
Intraluminal thrombosis caused by rupture of an atherosclerotic plaque in a 
coronary artery may precipitate necrosis of myocardial tissue. The eminent role of 
thrombosis in the coronary arteries has for long been disputed, but was established 
when Dewood showed occlusive thrombosis in the majority of coronary angio-
graphies during the acute phase of myocardial infarction. 12 The onset of acute 
infarction harbours several risks for fatal outcome. Electrical instability and pump 
failure contribute to the risk of death following acute myocardial infarction. 
However, following the recovery of the acute phase of myocardial infarction, 
patients remain at increased risk of death and arterial thrombo-embolism during 
many years." 
In view of the fact that recurrent acute thrombosis of the arterial vascular system 
represents the most frequent cause of cardiovascular complications after myocardial 
infarction, reduction of thrombin formation appears a rational way to prevent 
subsequent cardiovascular events. To test this hypothesis, the randomised, placebo-
controlled, double-blind ASPECT (Anticoagulants in the Secondary Prevention of 
Events in Coronary Thrombosis) trial was initiated in 1986. The aim of this trial 
was to assess the effects of long-term oral anticoagulant treatment on mortality and 
cerebro- and cardiovascular complications in hospital survivors of acute myocardial 
infarction. The main results of this trial are described in chapter 2. Since oral 
anticoagulant treatment is associated with an increased risk of bleeding, we 
investigated if it was possible to identify subsets of patients on the basis of clinical 
variables during admission that would have no benefit of anticoagulant treatment. 
The results of this subgroup analysis are presented in chapter 3. In chapter 4, 
results of earlier studies that assessed the merits of oral anticoagulant treatment in 
14 
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post myocardial infarction patients are pooled to combine the statistical power of 
the studies in a cumulative meta-analysis. Chapter 5 compares the prognostic 
factors and survival of ASPECT participants and eligible non-participants as to 
provide insight in the kind and magnitude of selection of patients for the ASPECT 
trial. Because oral anticoagulant treatment requires regular monitoring, it is 
generally thought to be expensive. In chapter 6 the medical costs associated with 
the use of oral anticoagulant treatment after myocardial infarction in our study 
population are estimated and compared with the medical costs of placebo patients. 
15 
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Abstract 
The use of long-term oral anticoagulant treatment after myocardial infarction 
remains controversial because of conflicting findings on mortality in previous trials 
and the increased risk of bleeding associated with anticoagulants. 
We have carried out a randomised, placebo-controlled, double-blind, multi-centre 
trial in 3,404 hospital survivors of myocardial infarction. Eligible patients were 
randomly assigned to anticoagulant (acenocoumarol or phenprocoumon) or placebo 
treatment within 6 weeks after discharge. The target prothrombin time was 2.8-4.8 
international normalised ratio. During mean follow-up period was 37 months (range 
6-76 months), there were 170 deaths among 1,700 anticoagulant-treated patients 
and 189 in 1,704 placebo-treated patients (hazard ratio 0.90 [95% ClO.73-1.1I]). 
Anticoagulant treatment led to significant reductions by comparison with placebo 
treatment in recurrent myocardial infarction (Il4 vs 242 patients; hazard ratio 0.47 
[0.38-0.59]) and cerebro-vascular events (37 vs 62; 0.60 [0.40-0.90]). Major 
bleeding complications were seen in 73 patients who received anticoagulants and 19 
who received placebo. 
We conclude that long-term anticoagulant treatment after myocardial infarction 
in low risk patients has a limited effect on mortality but achieves substantial benefit 
by reducing the risk of cerebro-vascular events and recurrent myocardial 
infarctions. 
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Introduction 
Patients who have sustained myocardial infarction are at increased risk of subse-
quent cardiovascular morbidity and death.! After the discovery of the anticoagulant 
effect of coumarin derivatives, many clinical trials were carried out in the 1950s 
and 1960s to assess the efficacy of oral anticoagulants in the prevention of car-
diovascular complications and death after myocardial infarction. The results of 
these trials were conflicting. Good results in some trials were questioned because 
of poor study design,'·' whereas inadequate anticoagulation in other trials could 
have obscured positive effects.' The debate was revived in 1980 by the Sixty Plus 
Reinfarction Study, which showed an increase in cardiovascular complications 
when long-term oral anticoagulant therapy after myocardial infarction was 
withdrawn. 7 Although that trial showed that withdrawal was detrimental, it 
provided no evidence that initiation of oral anticoagulant treatment after myocardial 
infarction was beneficial. A 1990 trial of post-infarction patients in Norway found 
substantial reductions in mortality (34%), and stroke (55%) with anticoagulant 
therapy by comparison with placebo.8 
We report here the results of a randomised, double-blind, placebo-controlled trial 
that assessed the effect of long-term oral anticoagulant treatment on mortality in 
3,404 hospital survivors of myocardial infarction. Secondary endpoints were 
vascular death, recurrent myocardial infarction, cerebro-vascular events and 
bleeding complications. 
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Patients and Methods 
Design 
Hospital survivors of acute myocardial infarction were emoled in the trial from 60 
Dutch hospitals from between September, 1986, and December, 1991. Patients 
were required to have rises in cardiac enzyme activities at least to twice the upper 
limit of normal with a typical serial pattern. Criteria for exclusion were an 
indication for oral anticoagulant treatment (e.g. left ventricular thrombus or 
aneurysm, chronic atrial fibrillation, cardiomyopathy), anticoagulant therapy within 
the six months before the qualifying myocardial infarction, increased bleeding 
tendency, anticipated coronary revascularisation procedure, malignant disease with 
poor prognosis, mental disorder, pregnancy, or oral anticoagulant treatment of 
other household members. 
After informed consent had been obtained at hospital discharge, the patient was 
referred to a regional thrombosis centre, a specialised centre for the monitoring of 
coumarin therapy of outpatients. At thrombosis centres patients were randomly 
assigned to treatment with a coumarin derivative or matching placebo. The choice 
of anticoagulant (acenocoumarol or phenprocoumon), was made before ran-
domisation at the discretion of the referring cardiologist in consultation with the 
thrombosis centre. Trial medication was started as soon as possible after hospital 
discharge but not later than six weeks afterwards; it was continued until the end of 
the trial (June 30, 1992). After the randomisation visit the patient was seen at the 
thrombosis centre once or twice a week until the prothrombin time was within the 
target range of 2.8-4.8 international normalised ratio (INR).,,10 At every visit to the 
thrombosis centre, a short history was taken and a blood sample was drawn for 
measurement of the prothrombin time by Thrombotest. II The time between visits 
was gradually lengthened to a maximum of eight weeks unless dose adjustment 
necessitated more frequent visits. A computer dose system at the thrombosis 
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centres made it possible to give identical dosage instructions and management of 
placebo and actively treated patients. Treatment allocation was double-blind. While 
on trial medication, patients were strongly advised not to take other anti-thrombotic 
medication. The study was approved by the Ethics Committees of the participating 
hospitals. 
Clinical EvellIs 
The clinical events were death, recurrent myocardial infarction, cerebro-vascular 
events, and major bleeding. Death was classified as vascular or non-vascular. 
Vascular death included instantaneous or sudden death (all deaths occurring within 
1 hour of onset of symptoms), unobserved and unexpected death, fatal recurrent 
myocardial infarction (death within 28 days after recurrent myocardial infarction), 
and death due to congestive heart failure, cerebm-vascular events, or extracranial 
bleeding. All other deaths were considered non-vascular. Recurrent myocardial 
ilifarction was diagnosed in the presence of at least two of a history of chest 
discomfort lasting longer than 30 min, serial cardiac enzyme pattern typical of 
myocardial infarction with at least one activity more than twice the upper limit of 
normal, or the development of new Q-waves (> 0.03 s) on the standard 12-lead 
electrocardiogram. Patients who survived the onset of symptoms of an acute 
myocardial infarction for at least I h but died subsequently were classified as 
having suffered a recurrent myocardial infarction. Cerebro-vascular events were 
classified as infarction or bleeding on the basis of the computed tomography scan 
or, if this was not available, as unspecified. If death occurred within 24 h of the 
onset of an unspecified cerebro-vascular event, a diagnosis of intracranial bleeding 
was made. 12 Functional outcome at discharge of stmke survivors was classified as 
no disability, mild, moderate, or severe disability." Cerebro-vascular lasting less 
than 24 h and leaving no residual symptoms were classified as transient ischaemic 
attacks. Vascular event was the composite endpoint of vascular death, recurrent 
23 
Chapter 2 
myocardial infarction, or cerebro-vascular event. Major bleeding was defined as 
intracranial or fatal bleeding or any bleeding that led to admission for hospital 
treatment. All events were reviewed by the members of the classification 
committee unaware of treatment allocation on the basis of a standard patient report. 
Data Analysis 
The primary endpoint was death from any cause and the secondary endpoints were 
vascular death, recurrent myocardial infarction, cerebro-vascular event, vascular 
event, and major bleeding. The main analysis considered all randomised patients 
irrespective of the actual therapy at the time of the endpoint 
("intention-to-treat" analysis). In this analysis, the incidence of endpoints was 
compared in terms of the hazard ratio (the risk of the endpoint per unit of time for 
patients assigned to oral anticoagulant treatment divided by the risk for those 
assigned to placebo treatment). Hazard ratios were calculated by the Cox 
proportional-hazards modeLl' For intention to treat analysis, censoring was applied 
when the patient died or at the end of follow up on June 30, 1992. For the 
"per-protocol" analysis we included only endpoints that occurred while the patient 
was on trial medication or within 28 days after its withdrawal. The size of the trial 
was such that 10% mortality in the placebo group could be distinguished from 
7.5 % mortality in the anticoagulant group with 80% power and a two-sided P value 
less than 0.05. The Data Monitoring Committee once a year sought evidence of 
beneficial or adverse effects of therapy according to a predefined statistical 
stopping guideline. IS 
Quality control of the anticoagulant effect was assessed by two methods. The 
cumulative method assessed the proportion of all prothrombin times that were 
within the target range. The other method assessed the proportion of time patients 
spent with the INR within the target range by taking a cross-section of the 
prothrombin times at four predefined times. 16 
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Results 
Patients 
Between Sept 1, 1986 and Dec 31, 1991 we randomised 3,404 patients from 60 
hospitals in the Netherlands at 19 regional thrombosis. The mean follow-up period 
was 37 (6-67) months. No patient was lost to follow-up. There were no differences 
in base-line characteristics between the treatment groups (table 1). 9% of patients 
had had a previous myocardial infarction and 25 % received thrombolytic agents 
during the index admission. ll-blockers were prescribed to 51 % of the patients at 
discharge. More than 90 % of patients underwent randomisation within 2 weeks of 
discharge, and the median time from discharge to randomisation was 4 days. 
The coumarin chosen before randomisation was phenprocoumon in 55 patients in 
each group and acenocoumarol in 45 of each group. 
In the actively treated group 5,241 patient-years of follow up were accumulated for 
the 1,700 patients; in the placebo group there were 5,200 patient-years of follow up 
for 1,704 patients. 
During follow-up there were 170 deaths in the actively treated group and 189 in the 
placebo-treated group (table 2), a reduction of 10%. (hazard ratio 0.90 [95% CI 
0.73-1.11]; table 3). There were 3 fatal episodes of extracranial bleedings (all 
gastrointestinal) in the anticoagulant group. Survival is shown in figure 1. 
Anticoagulant treatment significantly reduced the risk of recurrent myocardial 
infarction (tables 2 and 3). More than one recurrent myocardial infarction 
occurred in 13 anticoagulated-treated and 34 placebo-treated patients. Anticoagulant 
treatment also reduced the risk of a first cerebro-vascular event (tables 2 and 3). 
Cerebral infarction occurred in 15 anticoagulant treated (2 fatal) and 43 
placebo-treated patients (2 fatal) patients. However, cerebral haemorrhage was 
more common among anticoagulant treated patients (17 cases, 8 fatal) than among 
25 
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Table 1. Baseline characteristics of the randomised patients. • 
Mean 'ge (yr ±SD) 
Male (%) 
Randomization delayt (%) 
AC 
(n~ 1700) 
61 (±II) 
81 
< 2 wk 92 
2-4 wk 5 
4-6 wk 3 
Previous myocardial infarction (%) 9 
Diabetes mellitus (%) 8 
Current smokers (%) 53 
Thrombolytic agents used (%) 25 
Aspirin during admission (%) 28 
Highest enzyme values (median and 25% -75% quartiles)* 
CK 7.5 (4.3-13.2) 
ASAT 4.6 (2.7-7.6) 
LD 2.5 (1.7- 3.6) 
Q-wave infarction (%)1 77 
Anterolateral 46 
Inferoposterior 54 
Kitlip class III or IV (%)1 5 
B-Blocking agents at discharge (%) 51 
Coumarin congener (%) 
phenprocoumon 
acenocoumarol 
55 
45 
• No sIgnificant differences were detected for any of the comparisons shown. 
Placebo 
(n~ 1704) 
61 (±II) 
79 
94 
4 
2 
9 
7 
52 
25 
28 
7.1 (4.1-12.4) 
4.4 (2.6- 7.3) 
2.4 (1.6- 3.5) 
77 
46 
54 
5 
51 
55 
45 
AC denotes anticoagulants, CK creatine kInase, ASAT serum aspartate aminotransferase and lD lactate dahydrogenase. 
'Tima from hospital discharge to randomisation. 
, Expressed as multiple of the upper limit of normal. 
IQ-waves ~O.03 sea and ~O.1 mY. 
'Highest KHlip or MIRU class raeched in hospiteL 
placebo-treated patients (2 cases, neither fatal). Unspecified strokes occurred in 4 
anticoagulant group (1 fatal) and 12 in the placebo group (6 fatal). Of the 25 sur-
vivors of stroke in the anticoagulated group, 7 (28 %) were moderately or severely 
disabled at discharge, compared with 19 (39%) of the 49 survivors of stroke in the 
placebo group. There was a significant reduction with anticoagulation in the 
endpoint "vascular event" (tables 2 and 3). 
Major bleeding complications were more common in the anticoagulant group 
than in the placebo treated group. Gastro-intestinal bleedings accounted for about 
half of the extracranial major bleedings episodes. 
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Table 2. Incidence of major clinical events during follow-up ("intention-to-treat" analysis) 
AC Placebo 
Number of patients 1700 1704 
Years of follow~up 5241 5200 
Events (event rate) Events (event rate) HR (95% C.I.)' 
Death from any cause 170 (3.2/100py) 189 (3.6/100py) 0.90 (0.73-1.11) 
Vascular death 134 (2.5/100py) 142 (2.7/100py) 0.94 (0.75-1.20) 
Re<:urrent MI 114 (2.3/100py) 242 (5.1I100py) 0.47 (0.38-0.59) 
Cerebra-vascular event 37 (0.7/100py) 62 (1.2/100py) 0.60 (0.40-0.90) 
Vascular event* 239 (4.8/l00py) 366 (7.9/100py) 0.65 (0.55-0.76) 
Major bleeding' 73 (1.4/100py) 19 (0.4/100py) 3.87 (2.33-6.41) 
HR, hazard ratio; Cit oonfidenoe Interval; py, patlent-years; MI, myooardh,llnfarotion. 
'Endpoints occurring while tho patient WIlS on trial medloatlon (or within 28 days after Its cessation). 
!The hazard ratio estimates are indioated. 
IYasoulaf death/myooardlallnf8rotlon/oarebro-vosoular avant whlohever evant oocurred first. 
Iintracranial/axlrooranial bleoding whichever avant occuf(od first. 
Table 3. Contribution of events to clinical endpoints 
AC Placebo 
Number of Events 
Vascular death 134 142 
IlIslalllalJeOlls/Sudde/l 57 43 
UnobservedlUnexpected 12 21 
ReclllTelll MI 24 40 
Congestive heart failure 27 30 
Cerebro-wlSclilar event 11 8 
Et:tracraniai bleeding 3 0 
Cerebra-vascular event 37 62 
llltracrallial bleeding 17 2 
Cerebral jnfarction 15 43 
Unspecified 4 12 
TrallSiellt ischaemic attack 2 6 
M!\ior extracranial bleeding 56 17 
Gastroilltestinal 33 8 
Muscular 8 1 
Olher 15 8 
MI, myocardial infarction. 
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Event-free survival, including the occurrence of major bleeding, is shown in figure 2. 
At 3 years of follow-up event-free survival was significantly higher in the 
anticoagulant group than in the placebo group 83 vs 76% p< 0.0001, log-rank test). 
The findings of the per-protocol analyses are given in table 4. 
Table 4. Incidence of major clinical events during follow-up ("per protocol" analysis)' 
AC Placebo 
Number of patients 1700 1704 
Years of follow-up 3725 3488 
Events (event rate) Events (event rate) HR (95 % C.I.)! 
Death from any cause 91 (2.4/100py) 105 (3.0/100py) 0.86 (0.65-1.14) 
Vascular death 81 (2.2/100py) 99 (2.8/100py) 0.81 (0.61-1.09) 
Recurrent MI 86 (2.3/100py) 207 (6.1I100py) 0.41 (0.32-0.53) 
Cerebro3 vascular event 24 (O.6/100py) 42 (1.2/100py) 0.57 (0.34-0.93) 
Vascular event* 163 (4.4/iOOpy) 305 (9.0/100py) 0.53 (0.44-0.64) 
Mttior bleeding' 55 (1.5/100py) 6 (O.2/iOOpy) 9.05 (3.90-21.0) 
HR, hazard ratio; CI, confidence Interval; py, patienl-yaars; MI, myooardial infarotion. 
'Endpoints occurring whlle tha patlant was on trlel medication (or withIn 2B days aftar Its oessation). 
lTha hazard ratio estimates ara indioated, 
lVasoular death/myocardial infarction/cerabro-vascular evant whlohever avant ocourred first. 
llntraoranlallextractenlal bleeding whichever event occurred first. 
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Table 5. Reasons for discontinuation of trial medication 
No. of permanent discontinuations 
Reasons for discontinuation 
Deaths 
Non-fatal cerebra-vascular event 
Non-fatal myocardial infarction 
Non-fatal extrncranial bleeding 
Patient's refusal 
Physician's refusal 
Change of address 
Other 
% of patients still alive and 
still on medication 
at 3 months 
at 6 months 
at 1 year 
at 2 years 
at 3 years 
at 4 years 
AC 
768 
91 
12 
31 
81 
165 
301 
75 
12 
89 
82 
76 
64 
54 
48 
Placebo 
887 
103 
32 
124 
11 
170 
363 
70 
14 
85 
79 
70 
59 
48 
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By the cumulative method to assess adequacy of the anticoagulant treatment (57,634 
measurements), 62% of prothrombin times were within the target range; 29% were 
below 2.8 INR and 9% were above 4.8 INR. By the cross-sectional method (1,172 
measurements) we calculated that for 74% of patients' time, coagulation was within 
the therapeutic range « 2.8 INR for 20% and> 4.8 INR for 6% of the time). The 
commonest reasons for discontinuation of study medication are shown in table 5. 
After 3 years about half of the patients in each group had discontinued trial 
medication, mostly for non-medical reasons. Overall, patients were on trial medication 
for 71 % of time in the anticoagulant group and for 67% in the placebo group. 
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Discussion 
We have found that long-term oral anticoagulant treatment has only a moderate effect 
on mortality but strongly reduces cardiac and cerebro-vascular morbidity after 
myocardial infarction. The 10% mortality reduction we observed is much smaller than 
the 24 % reduction in the Norwegian trial.' In that trial mortality after mean follow-up 
of 3 years in placebo-treated patients was 20%, compared with 11 % in our trial. The 
better outcome in Our placebo-treated patients may be due to better left-ventricular 
function at baseline,I7·" or to recent improvements in medical care during the acute 
phase of (recurrent) myocardial infarction, leading to a lower fatality rate. 19•21 The 
significant reduction in recurrent myocardial infarction in anticoagulant-treated 
patients accords with previous reports; it is due mainly to a much lower rate of non-
fatal reinfarction. 
The increased risk of haemorrhagic stroke associated with long-term oral 
anticoagulant treatment has probably contributed to its limited use after myocardial 
infarction.22•23 Although we observed a higher rate of haemorrhagic stroke in 
anticoagulant-treated patients, overall stroke incidence was reduced by 40% mainly 
because of a 65 % lower rate of ischaemic stroke. Altogether, the incidence of fatal 
stroke in the two groups was similar, but the proportion of stroke survivors with 
moderate or severe disability at discharge was higher in placebo group. Thus, though 
the number of strokes in this trial was low, we suggest that anticoagulant treatment 
reduces the frequency of non-fatal stroke and improves subsequent functional 
outcome. 
The 35 % reduction in vascular events by oral anticoagulant treatment is equivalent 
to the prevention of 3 vascular events per 100 patient-years at the cost of one major 
bleeding event. The rate of bleeding complications (1.5 per 100 patient-years) is 
similar to findings of previous studies. '.24 The consistency of these data confirms the 
relative safety of long-term anticoagulant therapy with an INR range of 2.8-4.8, 
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provided adequate quality of oral anticoagulant treatment is achieved. 
It is difficult to assess the clinical impact of such diverse events as bleeding and 
thrombo-embolic complications. In an attempt to estimate the relative importance of 
such complications, Braunwald et al. have proposed an "unsatisfactory-outcome" 
endpoint score," to which cardiovascular complications during follow-up contribute an 
arbitrary weight varying from one (death) to zero (no events). If we use this weighting 
system for the major endpoints, the score was 24 % lower in the anticoagulant group 
than in the placebo group. Although it was primarily intended to compare the effects 
of different thrombolytic agents, we believe that this score supports our findings. 
Since this trial did not include patients treated with aspirin, no efficacy estimates 
for the comparison of anticoagulant and aspirin treatment can be derived from our 
data. The efficacy of long-term oral anticoagulant treatment and of aspirin after 
myocardial infarction has been directly compared in a few trials,"·27 but interpretation 
is limited by the open design and small size of these trials. Also, results may have 
been affected by poor quality of anticoagulation. We believe that a trial is now 
warranted that directly compares the efficacy and safety of long-term aspirin and 
coumarin treatment in a large group of patients who have sustained myocardial 
infarction. 
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Figure 1. Kaplan-Meier curves for death froIll any cause, according to assigned 
therapy. Numbers denote patients at risk (anticoagulated patients in top). 
32 
Main results 
100% 
90% 
coumarlns 
80% 
70% 
60% 
1700 1437 1115 817 485 234 
60% {1704 1370 1048 753 482 209 
1 2 3 4 6 
Years 
Figure 2. Kaplan-Meier curves for death, non-fatal myocardial infarction, non-fatal 
cerebra-vascular event or major bleeding, whichever occurred first, according to 
assigned therapy. 
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Efficacy of long-term anticoagulant therapy in 
subgroups of post myocardial infarction patients 
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Chapter 3 
Abstract 
Determination of clinical variables that identify subsets of patients who do not benefit 
from anticoagulant treatment could preclude them from unnecessary exposure to the 
potentially adverse effects of treatment. 
We analyzed the effect of anticoagulant treatment in subgroups of hospital survivors 
of myocardial infarction according to age, gender, history of hypertension, previous 
myocardial infarction, smoking habits, diabetes mellitus, Killip class, anterior location 
of infarction, thrombolytic therapy, and ll-blockers on the occurrence of recurrent 
myocardial infarction, cerebro-vascular event, vascular event (the composite endpoint 
of reinfarction, cerebro-vascular event and vascular death) and death from any cause. 
None of the investigated subgroups of patients showed significantly lesser beneficial 
effect from treatment for any of the clinical el)dpoints. The effect of treatment with 
respect to vascular event appeared to be smaller in females compared to men (-11 % 
vs -45%) and in diabetics compared to non-diabetics (-14% vs -42%). In a 
multivariate analysis higher age, previous myocardial infarction, diabetes mellitus, the 
use of thrombolytic agents and heart failure during admission were independently as-
sociated with an increased occurrence of cardiovascular complications during follow-
up. 
The relative benefit of long-term oral anticoagulant therapy in survivors of 
myocardial infarction is not modified by known prognostic factors for cardiovascular 
disease. 
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Introdnction 
Patients who survive an acute myocardial infarction carry an increased risk of arterial 
thrombo-embolism. Recent clinical trials have proven that long-term oral anticoagulant 
treatment with a target international normalised ratio (INR) of 2.8-4.8 reduces the 
incidence of such complications. I.' However, oral anticoagulant treatment has also 
been associated with an increased risk of bleeding complications which can sometimes 
be fatal or cause severe disability as in the case of intracranial haemorrhage.3.' 
Determination of clinical variables that identify subsets of patients who do not benefit 
from anticoagulant treatment could preclude them f!'Om unnecessary exposure to the 
potentially adverse effects of treatment. Results of·a recent subgroup analysis of the 
Warfarin Re-infarction Study indicated that the presence of diabetes mellitus and 
previous myocardial infarction could offset the beneficial effect of long-term warfarin 
treatment. In addition, it was also suggested that older patients had a relatively smaller 
benefit from treatment. 6 The ASPECT (Anticoagulants in the Secondary Prevention of 
Events in Coronary Thrombosis) trial investigated the effect of protracted an-
ticoagulant treatment relative to placebo in hospital survivors of myocardial infarction. 
In view of the results of the W ARIS subgroup analysis and their important 
implications we performed a subgroup analysis of the ASPECT patients. 
Methods 
Patients 
The present anaIysis is based on data of patients enroled in the ASPECT (Anticoa-
gulants in the Secondary Prevention of Events in Coronary Thrombosis) trial. Details 
of this randomised, double-blind, placebo-controlled trial that assessed the efficacy of 
long-term anticoagulant therapy after myocardial infarction have been published 
previously.' In short, the ASPECT trial comprised 3,404 hospital survivors of an 
41 
Chapter 3 
acute myocardial infarction who were randomised between September I, 1986 and 
December 31, 1991 to oral anticoagulant therapy with a coumarin derivative 
(phenprocoumon or acenocoumarol) or matching placebo within on average 4 days of 
discharge. To become eligible, patients required a cardiac enzyme level elevation of at 
least twice the upper reference limit. Patients with an indication for oral anticoagulant 
therapy (e.g. chronic atrial fibrillation, left ventricular thrombus or aneurysm, or car-
diomyopathy), or who were on anticoagulant treatment within a period of six months 
preceding the qualifying myocardial infarction, with increased bleeding tendency, 
anticipated revascularisation procedure, malignant disease with poor prognosis, mental 
disorder, pregnancy, or other household members receiving oral anticoagulant therapy 
were not eligible. Oral anticoagulant therapy was adjusted individually, with a 
prothrombin's target range of 2.8-4.8 INR. Treatment allocation was double-blind. 
Trial medication was continued until the end of the trial follow-up on June 30, 1992. 
The median duration of follow-up was 37 months. The major clinical outcome events 
were as follows: death occurred in 170 of the 1,700 anticoagulated patients and in 
189 of the 1,704 placebo patients, a reduction of 10 % (95 % confidence interval -11 to 
27%). Recurrent myocardial infarction was observed in 114 anticoagulated patients 
versus 242 placebo patients, a reduction of 53% (41 to 62%) and cerebro-vascular 
event in 37 anticoagulated patients versus 62 placebo patients, a reduction of 40% (10 
to 60%). Any vascular event occurred in 239 anticoagulated patients versus 366 
placebo patients, a reduction of 35% (24 to 45%). The study was approved by the 
ethical committees of the participating hospitals and all patients had given oral 
informed consent. 
Events 
The following endpoints were considered: recurrent myocardial infarction, 
cerebro-vascular event, vascular event and death from any cause. Recurrent 
myocardial ilifarctioll was defined as a history of chest discomfort with a duration 
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exceeding 30 minutes and serial enzyme pattern typical for myocardial infarction with 
at least one cardiac enzyme exceeding twice the upper reference limit, or the 
development of new Q-waves (> 0.03 secs) on the standard 12-lead electrocardio-
gram. Patients who survived the onset of symptoms of an acute myocardial infarction 
for at least one hour and died subsequently were also classified as having suffered a 
recurrent myocardial infarction. Cerebro-vascular ev~1It included haemorrhagic and 
ischaemic stroke and transient ischaemic attack. Vascular event was defined as the 
composite endpoint of either vascular death, recurrent myocardial infarction or 
cerebro-vascular event. All clinical events were blindly classified by a Mortality and 
Morbidity Classification Committee. 
Data Analysis 
Effect estimates of anticoagulant treatment in subgroups of variables known to affect 
long-term prognosis were calculated using the Cox model with the endpoint as the 
independent variable. Differences in effect of anticoagulant treatment in subgroups 
were investigated by the introduction of interaction terms in the model. In addition, 
interaction with anticoagulant therapy on the respective outcome events was assessed 
by a statistical comparison of the difference of coefficients associated with anticoagu-
lant therapy. The same variables were also introduced in a multivariate Cox 
proportional-hazards model to assess their independent association using the 
predefined endpoint as the independent variable. The following variables were 
considered for inclusion in the model: anticoagulant treatment, age, gender, smoking 
status on admission, diabetes (defined as a history of diabetes with hypoglycaemic 
medication at discharge), history of hypertension, previous myocardial infarction, 
highest Killip class during admission, anterior location of infarction, administration of 
thrombolytic agents, and the use of Jl-blockers at discharge. 
All analyses were performed according to the "intention-to-treat" principle. P-values 
< 0.05 were considered significant. 
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Results 
PatiellIS 
Baseline characteristics of the patients are presented in Table 1. No differences were 
observed between the therapy groups for any of the baseline variables. In both 
treatment groups, 9% of the patients had suffered a previous myocardial infarction 
before ern'olment, while approximately 25 % of the patients was treated with 
thrombolytic agents. In either group, 5% of the patients had suffered moderate to 
severe heart failure during hospital admission. 
Table 1. Baseline characteristics of randomised patients, according to therapy group. 
Mean age (yr ±SD) 
Male (%) 
Randomization delayt (%) 
< 2 wk 
2-6 wk 
Previous myocardial infarction (%) 
Diabetes mellitus (%) 
Current smokers (%) 
Thrombolytic agents used (%) 
Highest enzyme values as ratio of reference 
(median and 25% ~75% quartiles)* 
CK 
ASAT 
LD 
Q-wave infarction (%)1 
No 
Yes 
Anterolateral 
Inferoposterior 
Killip class III or IV (%)1 
B-B1ocking agents at discharge (%) 
Placebo 
(n~ 1700) 
61(± 11) 
79 
94 
6 
9 
7 
52 
25 
7.1 (4.1-12.4) 
4.4 (2.6- 7.3) 
2.4 (1.6- 3.5) 
23 
77 
46 
54 
5 
51 
Anticoagulants 
(n~1704) 
61 (± 11) 
81 
92 
8 
9 
8 
53 
25 
7.5 (4.3-13.2) 
4.6 (2.7-7.6) 
2.5 (1.7- 3.6) 
23 
77 
46 
54 
5 
51 
AC denotes anticoagulated, CK creatine kinase, ASAT serum aspartate aminotransferase Bnd LD lactate dehydrogenase. 
'Time from hospital discharge to randomization. 
'Exprnsed as multiple of the uppu limit of normal. 
'Q-waves ~O.03 se~ and ~O.l mY. 
IHighest Killip or MIRU class reached in hospital. 
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Treatment effect ill subgroups 
The relative effects of anticoagulant treatment within subgroups on the occurrence 
of various outcome events are shown in Tables 3 through 6. Relative reductions 
and statistical limits within subgroups are graphically displayed in Figures I 
through 4. The effect of treatment on reinfarction over the strata was fairly 
homogeneous, with some attenuation of the treatment effect in wonlen and patients 
with prior myocardial infarction (Table 3). For instance, the risk (hazard) of 
recurrent myocardial infarction associated with anticoagulant therapy in women was 
0.59 (95% confidence intervals 0.36, 0.96), indicating a risk reduction of 41 % 
relative to an observed risk reduction of 59% in men. Anticoagulant treatment 
appeared to have a smaller effect on cerebra-vascular events in patients with 
diabetes or hypertension but, due to the lower incidence of cerebro-vascular 
complications, the confidence intervals of the effect estimates were wider than for 
recurrent myocardial infarction (Table 4). This was in particular true for the 
number of cerebro-vascular events in subjects aged below 65 years. Obviously, the 
composite diagnosis vascular event included the highest number of endpoints (Table 
5). The calculated effect estimates suggested a particularly modest effect of 
treatment in women (risk reduction 11 %, 95 % CI -25 %, 36 %) and in patients with 
, 
diabetes mellitus (risk reduction 14%, 95% CI -36%, 45%), compared to risk 
reductions of 45% in men and 42% in non-diabetics, respectively. 
Anticoagulant treatment was not associated with a significant mortality reduction in 
any of the subgroups, although the effect estimate reached borderline significance 
in patients without clinical signs of acute heart failure, i.e. Killip class I (Table 6). 
Interaction of subgroups with treatment 
Introduction of interaction terms in the model provided no evidence for interaction 
of the selected variables with the effect of anticoagulant treatment for any of the 
endpoints. In accordance with these results, no effect modification could be 
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demonstrated in patients with previous myocardial infarction, diabetes and female 
gender by comparison of the coefficients in these subgroups. 
Predictors of evellls 
Results of the multivariate analysis are presented in Table 2. After adjustment, 
anticoagulant treatment was associated with a 56 % lower incidence of recurrent 
myocardial infarction (Relative Risk 0.44, 95% Confidence Interval 0.35, 0.55). 
Previous myocardial infarction, higher age, the presence of diabetes and the use of 
thrombolytic therapy were significantly associated with a higher incidence of 
recurrent myocardial infarction during follow-up. In a similar way, anticoagulant 
treatment was associated with a 39% lower incidence of cerebra-vascular events, 
while increasing age and diabetes were independent predictors of this outcome. The 
strongest predictors of death were higher age, diabetes, heart failure and previous 
myocardial infarction, while the use of Jl-blockers proved to be protective towards 
mortality. 
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Table 2. Adjusted risk estimates (and 95% confidence intervals) of prognostic factors in post myocardial infarction patients 
Recurrent MI Cerebra-vascular Event Vascular Event Mortality 
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) 
Anticoagulant therapy 0.44 (0.35,0.55) 0.61 (0.40,0.92) 0.61 (0.52,0.72) 0.90 (0.73,1.11) 
Age (increment of 1 year) 1.02 (1.01,1.03) 1.05 (1.03,1.08) 1.03 (1.02,1.04) 1.07 (1.05,1.08) 
Previous MI 2.00 (1.47,2.64) 1.08 (0.57,2.07) 1.79 (1.43,2.26) 1.67 (1.25,2.23) 
Diabetes 1.45 (1.03,2.05) 2.32 (1.39,3.90) 1.59 (1.24,2.04) 1.34 (0.96,1.85) 
Thrombolysis 1.42 (1.09,1.85) 0.69 (0.36,1.32) 1.01 (0.82,1,25) 0.73 (0.53,1.02) 
Kil1ip class > 1 1.02 (0.81,1.28) 0.88 (0.58,1.36) 1.22 (1.03,1.45) 1.67 (1.35,2.08) 
fi-Blockers 0.97 (0.78,1.21) 1.29 (0.85,1.95) 0.86 (0.73,1.07) 0.70 (0.56,0.87) 
Male gender LlO (0.84,1.45) 0.72 (0.46,Ll4) 1.00 (0.81,1.21) 1.06 (0.82,1.37) 
Smoking 1.06 (0.85,1.33) 0.95 (0.61,1.48) 1.00 (0.84,1.19) 1.09 (0.86,1.36) 
Hypertension 1.06 (0.82,1.37) Ll9 (0.76,1.87) 1.11 (0.91,1.34) 1.16 (0.90,1.48) 
Anterior infarction 0.91 (0.71,U7) 0.96 (0.60,1.53) 1.04 (0.87,1.26) 1.08 (0.75,1.37) 
RR: Relative Risk, CI: Confidence Interval 
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Table 3. Effect of anticoagulant treatment on Recurrent Myocardial Infarction in subgroups. 
---------------~-----~---------------------------------------~---- --------------
VARIABLE RECURRENT MYOCARDIAL INFARCTION 
PLACEDO (%) ANTICOAOULANTS (%) HR (95% eI) 
no. of events I no. of patients 
Age (yr) 
<55 59/490 (12.0) 30/507 (5.9) 0.47 (0.30-0.74) 
55-65 821623 (13.1) 34/601 (5.7) 0.42 (0.28-0.63) 
>65 101/591 (17.0) 491591 (8.3) 0045 (0.32-0.64) 
Sox 
Male 194/1350 (14.4) 87/1369 (6.4) 0.41 (0.32-0.54) 
Female 48/354 (13.6) 26/330 (7.9) 0.59 (0.36-0.96) 
CUrrent Smoking 
No 118/816 (14.5) 58/806 (7.2) 0,48 (0.35-0.66) 
Yo. 124/888 (14.0) 55/893 (6.2) 0,42 (0.30-0.57) 
Diabetes 
No 216/1579 (13.7) 100/1565 (6.3) 0.45 (0.35-0.57) 
Yo. 26f125 (20.8) 13/134 (9.7) 0.43 (0.22-0.85) 
Medical history of 
Hypertension 
No 178/1309 (13.6) 92/1310 (7.0) 0.49 (0.38-0.64) 
Yo. 64/395 (16.2) 211389 (5.4) 0.32 (0.19-0.52) 
Previous Myocardial 
Infarction 
No 20811554 (13.4) 9011542 (5.8) 0.42 (0.32-0.54) 
Yo. 341150 (22.7) 23/157 (14.6) 0.64 (0.36-1.05) 
Killip Class 
I 15111124 (13.4) 75/1114 (6.7) 0.48 (0.36-0.64) 
~ll 911580 (15.7) 38/585 (6.5) 0.39 (0.27-0.58) 
Anterior infarction'" 
No 186/1286 (14.5) 83/1299 (6.4) 0.42 (0.32-0.55) 
Yo. 56/418 (13.4) 301400 (7.5) 0.54 (0.34-0.85) 
Thrombolytic Therapy 
No 17811285 (13.9) 87/1280 (6.8) 0.47 (0.36-0.61) 
y" 64/419 (15.3) 26/419 (6.2) 0.39 (0.24-0.61) 
fi-blockers 
No 128/835 (15.3) 56/833 (6.7) 0.42 (0.31-0.58) 
Yo. 114/869 (13.1) 57/866 (6.6) 0.48 (0.34-0.66) 
--~--~-~----------~-------------------~~---~-----~-~----------
HRj Hazard Ratio, '" defined by Q wave> 0.03 sec in V2, V3 or V4. 
48 
Subgroup analysis 
Table 4. Effect of anticoagulant treatment on Cerebro-vascular Event in subgroups. 
----------------------------------------------- --------------------------------------------------------
VARIABLE CEREBRO-VASCUlAR EVENT 
PLAelmO (%) ANTICOAGULANTS (%) HR (95% CO 
no. of events I no. of patients 
Age (yr) 
<55 3/490 (0.6) 7/507 (1.4) 2,26 (0.57-8.98) 
55-65 19/623 (3.0) 111601 (1.8) 0.61 (0.29-1.30) 
>65 40/591 (6.8) 19/591 (3.2) 0.45 (0.26-0.78) 
Sox 
Male 40/1350 (2.0) 24/1369 (1.8) 0.58 (0.35-0.98) 
Female 22/354 (6.2) 13/330 (3.9) 0.65 (0.32-1.30) 
Current Smoking 
No 40/816 (4.9) 20/806 (2.5) 0,51 (0.30-0.89) 
Yo. 22/888 (2.5) 17/893 (1.9) 0.75 (0.39-1.43) 
Diabetes 
No 52/1579 (3.3) 27/1565 (1. 7) 0.52 (0.32-0.83) 
Yes 101125 (8.0) 10/134 (7.5) 0.91 (0.37-2.23) 
Medical history of 
Hypertension 
No 4511309 (3.4) 24/1310 (1.8) 0,52 (0.31-0.86) 
Yes 17/395 (4.3) 13/389 (3.3) 0.81 (0.39-1.69) 
Previous Myocardial 
Infarction 
No 54/1554 (3.5) 34/1542 (2.2) 0.63 (0.41-0.97) 
Yo. 8/150 (5.3) 3/157 (1.9) 0.35 (0.09-1.35) 
Kiltip Class 
1 38/1124 (3.3) 25/1114 (2.2) 0.61 (0.39-1.10) 
;,11 24/580 (4.1) 12/585 (2.1) 0.48 (0.25-0.94) 
Anterior infarction* 
No 45/1286 (3.5) 29/1299 (2.2) 0.63 (0.39-1.02) 
Yo. 17/418 (4.1) 8/400 (2.0) 0.50 (0.20-1.13) 
Thrombolytic Therapy 
No 55/1285 (4.3) 33/1280 (2.6) 0.60 (0.38-0.92) 
Yes 7/419 (1.7) 4/419 (1.0) 0.56 (0.16-1.97) 
Jl·bloekers 
No 27/835 (3.2) 19/833 (2.3) 0.70 (0.38-1.28) 
Yo. 35/869 (4.0) 18/866 (2.1) 0.51 (0.28-0.91) 
------------~- --------~ -----------------------------------------------------
HRi Hazard Ratio, * deHned by Q wave> 0,03 sec in V2, V3 or V4. 
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Figure 1. Effect estimates (vertical bars) and confidence intervals (horizontal 
bars) of oral anticoagulant treatment with respect to recurrent myocardial 
infarction in clinically defined subgroups of patients. 
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Figure 2. Effect estimates and confidence intervals of oral anticoagulant 
treatment with respect to cerebro-vascular event in clinically defined subgroups 
of patients. 
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Table 5. Effect of anticoagulant treatment on Vascular Event in subgroups. 
----~-------------------------------------------------------------------
VARIAIlLE VASCULAR EVENT 
PLACEBO (%) ANTICOAGULANTS (%) HR (95% CI) 
no. of events I no. of patients 
Age (yr) 
<55 76/490 (15.5) 42/507 (8.3) 0,50 (0.34·0.74) 
55-65 120/623 (19.3) 72/601 (12.0) 0.61 (0.45·0.82) 
>65 170/591 (28.8) 124/591 (21.0) 0.65 (0.52·0.83) 
Sox 
Male 286/1350 (21.2) 172/1369 (12.6) 0,55 (0.45·0.67) 
Female 80/354 (22.6) 66/330 (20.0) 0.89 (0.64·1.25) 
Current Smoking 
No 190/816 (23.3) 131/806 (16.3) 0.67 (0.53·0.84) 
Yeo 176/888 (19.8) 107/893 (12.0) 0.56 (0.44·0.72) 
Diabetes 
No 327/1579 (20.7) 200/1565 (12.8) 0.58 (0.49·0.70) 
Yes 39/125 (31.2) 38/134 (28.4) 0.86 (0.55·1.36) 
Medical history of 
Hypertension 
No 275/1309 (21.0) 177/1310 (13.5) 0.49 (0.38·0.64) 
Yo. 911395 (23.0) 61/389 (15.7) 0.32 (0.19·0.52) 
Previous Myocardial 
Infarction 
No 310/1554 (19.9) 20211542 (13.1) 0.62 (0.52·0.75) 
Yo. 56/150 (37.3) 36/157 (22.9) 0.55 (0.36·0.84) 
Killip Class 
1 224/1124 (19.9) 130/1114 (11.7) 0.55 (0.44·0.69) 
~1I 142/580 (24.5) 108/585 (18.5) 0.71 (0.55·0.91) 
Anterior infarction 
No 273/1286 (21.2) 169/1299 (13.0) 0.58 (0.47·0.70) 
Yo. 93/418 (22.2) 69/400 (17.3) 0.73 (0.53·1.01) 
Thrombolytic Therapy 
No 290/1285 (22.6) 200/1280 (15.6) 0.65 (0.54·0.78) 
Yo. 76/419 (18.1) 38/419 (9.0) 0.47 (0.32·0.70) 
fi-blockers 
No 198/835 (23.7) 138/835 (16.6) 0.66 (0.53·0.82) 
y" 168/869 (19.3) 100/866 (11.5) 0.56 (0.43·0.72) 
-------------------------_._._--------------------
HRj Hazard Ratio, ,., deftnoo by Q wave> 0,03 sec in V2, V3 or V4. 
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Table 6. Effect of anticoagulant treatment on Mortality in subgroups. 
---------------------~--~--------------~--------~-------------------
VARIABLE MORTALITY 
PlACBBO (%) ~COAOULANTS(%) HR (95% CI) 
no. of events I no. of patients 
Age (yr) 
<55 24/490 (4.9) 13/507 (2.6) 0.51 (0.26-1.02) 
55·65 50/623 (8.0) 47/601 (7.8) 1.01 (0.67·1.52) 
>65 1151591 (19.5) 109/591 (18.4) 0.95 (0.70·1.29) 
Sox 
Male 14411350 (10.7) 122/1369 (8.9) 0.82 (0.64-1.04) 
Female 45/354 (12.7) 47/330 (14.2) 1.18 (0.78-1.79) 
Current Smoking 
No 109/816 (13.4) 94/806 (11.7) 0.89 (0.67-1.17) 
y" 80/888 (9.0) 75/893 (8.4) 0.91 (0.66-1.25) 
Diabetes 
No 17011579 . (10.8) 14411565 (9.2) 0.85 (0.68-1.07) 
y" 19/125 (15.2) 251134 (18.7) 1.19 (0.65-2.19) 
Medical history of 
Hypertension 
No 146/1309 (11.1) 12111310 (9.2) 0.81 (0.64-1.04) 
y" 43/395 (10.9) 48/389 (12.3) 1.16 (0.76-1.76) 
Previous Myocardial 
Infarction 
No 156/1554 (10.0) 143/1542 (9.3) 0.92 (0.73-1.16) 
y" 33/150 (22.0) 26/157 (16.6) 0,73 (0.43-1.24) 
Killip Class 
1 98/1124 (8.7) 72/1114 (6.5) 0.73 (0.54-1.00) 
;,II 911580 (15.7) 97/585 (16.7) 1.06 (0.79-1.42) 
Anterior infarction 
No 133/1286 (10.3) 12111299 (9.3) 0.90 (0.70-1.15) 
y" 561418 (13.4) 48/400 (12.0) 0.88 (0.59-1.30) 
Thrombolytic Therapy 
No 166/1285 (12.9) 148/1280 (11.6) 0.88 (0.70-1.11) 
y" 23/419 (5.5) 21/419 (5.0) 0.94 (0.51-1.72) 
ll-blockers 
No 93/835 (11.1) 911833 (10.9) 1.00 (0.73-1.32) 
y" 49/869 (5.6) 42/866 (4.9) 0,85 (0.56-1.30) 
----------------------------------------------------------~-~--------------------
HRi Hazard Ratio, '* defmed by Q wave> 0.03 sec in V2, V3 or V4. 
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Figure 3. Effect estimates and confidence intervals of oral anticoagulant 
treatment with respect to vascular event in clinically defined subgroups of 
patients. 
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Figure 4. Effect estimates and confidence intervals of oral anticoagulant 
treatment with respect to mortality in clinically defined subgroups of patients. 
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Discussion 
From the findings of this subgroup analysis it appears that the relative effect of 
long-term oral anticoagulant treatment on various thrombo-embolic endpoints after 
myocardial infarction does not differ in a statistically significant manner among 
subgroups of patients. Nevertheless, our data suggest that anticoagulant treatment 
may be less efficacious with respect to the prevention of vascular events in females 
and diabetics. 
Some limitations of subgroup analysis should be noted at this point to clarify 
these results. Foremost, statistical power in subgroups may be negatively affected 
by the small number of patients or endpoints available for analysis, as in this case 
with respect to stroke. Also, when several subgroups are investigated without prior 
hypothesis, multiple testing may increase the risk of false positive results merely by 
chance. Further, the clustering of risk factors with a negative impact on outcome in 
particular subgroups of patients may confound the treatment effect as well. 
Therefore, results of subgroup analyses should always be interpreted with caution. 
In our subgroup analysis, both the introduction of interaction terms and the 
comparison of the coefficients in the subgroups of females and diabetics failed to 
show interaction, indicating that the suggested limited benefit could simply be the 
result of chance. 
In spite of their potentially important clinical implications, subgroup analyses of 
anticoagulant treatment after myocardial infarction are scarce, probably because 
only a few trials were of sufficient size to permit such an analysis. The 
International Anticoagulant Review Group addressed this problem by pooling data 
of nine controlled studies.' Interestingly, this study also reported a small treatment 
effect of anticoagulation in women. 
We did not establish interaction of previous myocardial infarction with the effect of 
anticoagulant treatment on mortality or recurrent myocardial infarction. These 
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findings are in accordance with the results of the Veterans Administration Study' 
but are distinct from the outcome of the subgroup analysis of the Warfarin Re-
infarction Study. Moreover, in that study recurrence of myocardial infarction was 
not reduced by anticoagulant treatment in the presence of diabetes.' As discussed 
earlier, our findings point to an (not significantly) attenuated effect of anticoagulant 
treatment with respect to vascular events in patients with diabetes mellitus but no 
interaction was demonstrated with respect to recurrent myocardial infarction alone. 
Although similar in design, the WARTS trial showed a much higher overall event 
rate of cardiovascular endpoints than the ASPECT trial, which in part could 
explain these disparities in outcome of the respective subgroup analyses. 
A multivariate analysis was performed to identify variables that showed an indepen-
dent association with the selected endpoints, but one should recognize that these 
associations pertain only to the patient group under investigation as any patient 
population of a clinical trial may be subjected to selection bias. Our multivariate 
analysis confirmed the association of increasing age, previous myocardial 
infarction, diabetes and clinical signs of heart failure during admission with 
cardiovascular morbidity and mortality after myocardial infarction,IO·12 and the 
beneficial effect of 1l-blockers. 13.14 The lack of the previously reported association 
of variables such as thrombolysis and anterior infarction with mortality probably 
resulted from selection of low risk patients in this trial, although the effect estimate 
of thrombolysis corresponds with earlier findings. 15. I' 
Tn view of the fact that none of the considered variables showed a significant 
modification of treatment effect it may be argued that all patients have equal 
relative benefit from anticoagulant treatment. Although this in itself may be a valid 
statement, multivariate analysis revealed a number of distinct features that may 
refer to patients who may carry an increased risk for subsequent cardiovascular 
events. In this respect it is of particular importance to notice that thrombolysis 
confers a profound reduction in mortality during the acute phase but may otherwise 
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increase the risk of recurrent myocardial infarction after hospital discharge. 
In summary, the results of this analysis suggest that the effects of anticoagulant 
treatment after myocardial infarction are not modified in clinically defined 
subgroups of patients while certain features characterize patients who carry an 
increased risk of cardiovascular complications. 
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Cumulative meta-analysis of long-term 
anticoagulant treatment after myocardial infarction 
Chapter 4 
Abstract 
The efficacy of long-term anticoagulant treatmcnt in patients after myocardial 
infarction has been investigated in numerous trials over the past decades. As most 
trials were of insufficient size to supply convincing results we have carried out a 
cumulative meta-analysis of 15 prospective follow-up studies that compared 10ng-
term anticoagulant treatment with standard therapy. 
Data of consecutive studies were combined according to an intention-to-treat 
analysis with the Mantel-Haensze1 method for assessment of relative risk. Death 
from all causes, recurrent myocardial infarction and cerebra-vascular stroke were 
assessed in 4,294 patients discharged after myocardial infarction on anticoagulant 
treatment and compared with 4,125 patients on reference therapy. 
Long-term anticoagulant therapy reduced mortality with 10% (relative risk 0.90; 
95% confidence interval 0.81-0.99), recurrent myocardial infarction with 43% 
(0.57; 0.50-0.64), and stroke with 45% (0.55; 0.40-0.65) in randomised trials. 
Statistical significance was reached for mortality in 1994, for reinfarction in 1964 
and for stroke in 1990. 
This cumulative meta-analysis provides evidence for a moderate reduction in 
mortality and a substantial reduction in recurrent myocardial infarctions and 
cerebra-vascular events by long-term oral anticoagulant treatment in patients after 
myocardial infarction. 
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Introduction 
A large number of trials on long-term oral anticoagulant treatment after myocardial 
infarction has been conducted over the last 40 years, but the controversy regarding 
the efficacy of this mode of therapy has not been resolved. I·" Based on results of 
small sized trials showing inconclusive results with respect to mortality and 
recurrence of myocardial infarction, some investigators concluded that long-term 
oral anticoagulant therapy after hospital discharge was not effective. 14,15,21,24," 
However, when the results of the Sixty Plus trial showed a detrimental effect of 
cessation of long-term oral anticoagulants after myocardial infarction,16 it was 
suggested that new trials were in order to settle the issue?' A study in Norwegian 
patients in 1990 showed a significant 24% mortality reduction and a substantial 
reduction in thrombo-embolic events." Yet, the recent ASPECT trial comprising 
over 3,400 Dutch patients showed a non-significant 10% mortality reduction.'o 
In view of these ambiguous results, we performed a cumulative meta-analysis to 
assess the efficacy of long-term oral anticoagulant treatment for reduction of 
mortality and morbidity after myocardial infarction. 
Methods 
Selectioll of studies 
Studies, reported in English, on the efficacy of long-term oral anticoagulant therapy 
in hospital survivors of myocardial infarction were identified by Medline searches 
from January 1963 to June 1, 1994 (keywords: 'myocardial infarction'; 
'anticoagulants'), and by reviewing reference lists of relevant papers. We selected 
studies with a prospective follow-up design in which treatment was initiated within 
six months following myocardial infarction and in which a comparison was made to 
standard therapy or placebo. Consequently, trials with a randomisation window of 
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more than six months,8,16 with a reference group treated with antiplatelet drugs/8 
and with enrolment of patients with other forms of coronary disease such as 
unstable angina pectOlis",6 were excluded. A total of 15 prospective follow-up 
studies remained available for analysis, Subsequent to this selection, three sets of 
studies were formed: a first set comprised all IS studies that met the selection 
criteria described above; a second group included all randomised trials; a third set 
consisted of randomised, double-blind and placebo-controlled trials. 
Statistical methods 
For each study the number of patients and endpoints in each treatment group were 
assessed. The relative risk and the 95 % confidence interval (el) of the event rate 
associated with anticoagulant treatment were calculated for each individual study. 
Subsequently, a cumulative meta-analysis was performed using the 
Mantel-Haenszel method," Overall 95% confidence intervals estimates were 
calculated by the test-based method according to Miettinen." Endpoints considered 
separately in this meta-analysis were total mortality, recurrent myocardial infarction 
and cerebro-vascular event. All studies were analyzed according to the 
intention-to-treat principle, 
Results 
Study populations 
Details of the selected 15 studies are presented in Table 1. The following coumarin 
derivatives were used: dicoumarol, phendione, phenprocoumon, warfarin and 
acenocoumarol. In some trials an ineffective dose of the coumarin derivative was 
employed instead of placebo for comparison with anticoagulant therapy,',5,9 Various 
methods were applied to measure the intensity of anticoagulant therapy. 
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Table l. Characteristics of studies that assessed the effect of long-term anticoagulant therapy after myocardial infarction 
Study First author Year of Design Follow-up Treatment Target Range 
No. publication (months) (% in range) 
1. Bjerkelund1 1957 non randomised 37 conventional vs 10-20% P&P 
open dicoumarol (46%) 
2. MacMillan' 1960 randomised 13 ineffective vs Doubling l-stage PT 
open effective dicoumarol (unknown) 
3. HarvaId4 1962 non randomised 31 placebo vs 10-25% P&P 
open phenprocoumon or (85%) 
dicoumarol 
4. B.M.R.C.' 1964 randornised 25 ineffective vs Doubling l-stage PT 
open effective phenindione (46%) 
5. Conrnd' 1964 randomised 10 placebo vs 1.5 time I-stage PT 
double-blind pbenprocoumon (82%) 
6. LoveW 1967 randomised 18 ineffective vs 15-30% Prothrombin 
open effective phenprocoumon activity (67%) 
7. Ebert" 1969 :rnndomised 53 placebo vs Doubling I-stage PT 
single blind dico~lorvr.uf.uin (82%) 
8. S0renSeD.1l 1969 non randomised 17 placebo vs 10-30%. P&P 
open dicoumaroI (74%) 
9. Meuwissenl2 1969 randomised 20 placebo vs 5-15%, IT 
double-blind phenprocoumon (91%) 
10. Ritland 13 1969 randomised 12 phenQione 3 months vs 10-25%, P&P 
open phendione 12 months (80%) 
II. Seaman" 1969 randomised 73 placebo YS 10-30%, P&P 
double-blind phenindione (61 %) 
12. Mersk.eylS 1974 randomised 12 placebo vs < 10%, IT 
open anticoagulant (58%) 
13. Breddin11 1980 randomised 24 placebo vs 5-12%, IT 
open phenprocoumon (58%) 
14. Smith19 1990 randomised 37 placebo vs 5-10%, IT 
double-blind warfarin (67%) 
15. ASPECT' 1994 randomised 37 placebo vs 5-10%, IT 
double-blind phenprocoumon or (74%) 
acenocoumarol 
P&P: Prothrombin-Proconvertm-Stuart factor activity. PT: Prothrombin time. IT: Tbrombo Test 
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The target range for optimal therapy varied considerably as did the proportion of 
patients with the INR in the target range. The mean follow-up ranged from 12 
months to 53 months. 
Effect all mortality 
Mortality data of each of the 15 selected studies are shown in Table 2. A 
statistically significant reduction in mortality was reported in three studies.'·'·l9 The 
cumulative relative risks of mortality in the three sets of studies are shown in Table 
3. The total number of subjects in the anticoagulated group and control group 
comprised 4,294 patients versus 4,125 patients in the set of pl'Ospective studies, 
3,891 patients versus 3,742 patients in the randomised trials and 2,515 patients 
versus 2,502 patients in the randomised, double-blind, placebo-controlled trials. 
The cumulative relative risk of mortality associated with anticoagulant treatment in 
all 15 prospective studies was 0.87 (95% CI 0.79-0.95), in the 12 randomised trials 
0.90 (0.81-0.99) (Figure I) and in the randomised, double-blind placebo-controlled 
trials 0.85 (0.74-0.98). 
Effect on recurrent myocardial ilifarctioll 
Since two studies did not report the number of recurrent infarctions,I4·1l the number 
of subjects for analysis of this endpoint comprised 4,031 anticoagulated patients 
and 3,952 reference patients in prospective studies. The relative risk for recurrent 
infarction associated with oral anticoagulant treatment did not reach statistical 
significance in eight of thirteen studies (Table 4). The cumulative relative risk was 
0.59 (0.53-0.66) for all prospective studies. The 10 randomised trials that reported 
on recurrent infarction showed a slightly lower cumulative relative risk of 0.57 
(0.50-0.64), as illustrated in Figure 2. Four trials that were conducted with a 
randomised, double-blind, placebo-controlled design yielded a cumulative relative 
risk of 0.55 (0.47-0.64). 
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Table 2. Relative risk of mortalily associated with long-term anticoagulant therapy in 
hospital survivors of myocardial infarction in individual studies. Numbers 
denote evenls per total number of patients in each trealmenl group. 
Study Anticoagulant Reference Individual RR 
No. group group (95% CI) 
~---------------------------------------------------------------------------------------------------------------------------_.--------
1. Bjerkelund 24/119 42/118 0.57 (0.37-0.87) 
2. MacMillan 8/27 0/23 
3. Harvald 34/145 451170 0.89 (0.60-1.30) 
4. n.M.R.C. 29/195 40/188 0.70 (0.45-1.08) 
5. Conrad 9/52 8/34 0.74 (0.31-1.72) 
6. Lovell 33/172 39/178 0.88 (0.58-1.32) 
7. Ebert 120/385 114/350 0.96 . (0.77-1.18) 
8. Sorensen 15/139 19/95 0.54 (0.29-1.01) 
9. Meuwissen 1/68 8/70 0.13 (0.02-1.00) 
10. Ritland 8/102 7/106 1.19 (0.45-3.16) 
11. Seaman 36/88 31/87 1.15 (0.79-1.68) 
12. Merskey 18/175 10/86 0.88 (0.43-1.83) 
13. Breddin 39/320 32/309 1.18 (0.76-1.83) 
14. Smith 94/607 123/607 0.76 (0.60-0.98) 
15. ASPECT 17011700 189/1704 0.90 (0.74-1.10) 
RR: Relative Risk, CI: Confidence Interval, _A: not available 
Table 3. Cumulative relative risk of mortality in the presence of long-term oral 
anticoagulant therapy in hospital survivors of myocardial infarction. 
Study 
No. 
Prospective studies Randomised trials Randomised. Double-blind 
Placebo-controlled trials 
--------------------------------------------------------------.-----------------------------------------------------------------------
RR (95% CI) RR (95% CI) RR (95% CI) 
I. Bjerkelund 0.57 (0.37-0.87) 
2. MacMillan 0.72 (0.49-1.07) 
3. Harvald 0.80 (0.61-1.06) 
4. n.M.R.C. 0.77 (0.61-0.97) 0.86 (0.57-1.29) 
5. Conrad 0.77 (0.60-0.96) 0.83 (0.58-1.20) 0.74 (0.31-1.72) 
6. Lovell 0.79 (0.65-0.96) 0.85 (0.65-1.12) 
7. Ebert 0.86 (0.74-0.99) 0.91 (0.77-1.08) 
8. Sorensen 0.84 (0.73-0.96) 
9. Meuwissen 0.82 (0.71-0.94) 0.88 (0.75-1.04) 0.46 (0.22-.098) 
10. ruttand 0.83 (0.72-0.95) 0.89 (0.76-1.05) 
11. Seaman 0.85 (0.75-0.97) 0.92 (0.79-1.08) 0.90 (0.64-1.26) 
12. Merskey 0.86 (0.75-0.97) 0.92 (0.80-1.07) 
13. Dreddin 0.88 (0.78-1.00) 0.95 (0.83-1.09) 
14. Smith 0.85 (0.76-0.95) 0.90 (0.79-1.01) 0.80 (0.66-0.98) 
15. ASPECT 0.87 (0.79-0.95) 0.90 (0.81-0.99) 0.85 (0.74-0.98) 
RR: Relative Risk; CI: Confidence Interval 
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Table 4. Relative risk of recurrent myocardial infarction associated with long-term 
anticoagulant therapy in hospital survivors of myocardial infarction in individual 
studies. Numbers denote events per total number of patients in each treatment 
group. 
Study 
No. 
I. Djerkelund 
2. MacMillan 
3. Harvald 
4. B.M.R.C. 
5. Conrad 
6. Lovell 
7. Ebert 
8. Sorensen 
9. Meuwissen 
10. Ritland 
13. Breddin 
14. Smith 
15. ASPECT 
Anticoagulated Reference 
group group 
221II9 381II8 
6127 4123 
521145 67/170 
341195 811188 
9/52 6134 
121172 171178 
601385 73/350 
7/139 18/95 
5/68 7/70 
51102 91106 
161320 251309 
821607 1241607 
114/1700 24211704 
Individual RR 
(95% CI) 
0.57 (0.36·0.91) 
1.28 (0.41-3.98) 
0.91 (0.68-1.21) 
0.40 (0.29·0.57) 
0.98 (0.38-2.51) 
0.73 (0.36-1.48) 
0.75 (0.55-1.02) 
0.27 (0.12·0.61) 
0.74 (0.25·2.20) 
0.58 (0.20·1.66) 
0.62 (0.34-1.13) 
0.66 (0.51-0.85) 
0.47 (0.38·0.58) 
RR: Relative Risk, CI: Confidence Interval 
Table 5. Cumulative relative risk of recurrent myocardial infarction in the presence of 
long-term oral anticoagulant therapy in hospital survivors of myocardial 
infarction. 
Study Prospective studies Ralldomised trials Randomised, Double-blind 
Placebo-controlled trials 
..... _._----------------------------------------------------------------------------------------.----------.. ---------.-------,-------
RR (95% CI) RR (95% Cl) RR (95% CI) 
I. Bjerkelund 0.57 (0.36·0.91) 
2. MacMillan 0.65 (0.43·0.98) 1.28 (0.41·3.98) 
3. Harvald 0.80 (0.63-1.02) 
4. B.M.R.C. 0.63 (0.52·0.76) 0.45 (0.33-0.61) 
5. Conrad 0.64 (0.53·0.71) 0.49 (0.37-0.66) 0.98 (0.38-2.51) 
6. Lovell 0.65 (0.54-0.71) 0.53 (0.40-0.69) 
7. Ebert 0.67 (0.58-0.79) 0.62 (0.50-0.75) 
8. Sorensen 0.65 (0.55-0.75) 
9. Meuwissen 0.65 (0.56-0.75) 0.62 (0.51-0.76) 0.86 (0.42- I. 76) 
10. Ritland 0.65 (0.56-0.75) 0.62 (0.51-0.75) 
13. Breddin 0.64 (0.56·0.74) 0.62 (0.51-0.75) 
14. Smith 0.65 (0.57-0.74) 0.63 (0.55-0.74) 0.68 (0.54-0.86) 
15. ASPECT 0.59 (0.53-0.66) 0.57 (0.50-0.64) 0.55 (0.47-0.64) 
------.--._---------_._ .... _ ... _ ... _ .. _._._----------------------------------------------._----_ .. _-_._ ......... _ .. __ ._._._._--_._----
RR: Relative Risk; CI: Confidence Interval 
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Effect on stroke 
Risk reductions with respect to cerebro-vascular events are shown in Table 6. Eight 
studies reported on the incidence of stroke in sufficient detail for risk estimate 
calculation. The cumulative relative risk was 0.51 (0.38-0.68) for all prospective 
studies, 0.56 (0.41-0.76) for randomised . trials and 0.54 (0.39-0.73) for 
randomised, double-blind, placebo-controlled trials (Table 7). 
Table 6. Relative risk of stroke associated with long-term anticoagulant therapy in 
hospital survivors of cerebro-vascular stroke in individual studies. Numbers 
denote events per total number of patients in each treatment group. 
Study 
No. 
1. Bjerkelund 
3. Harvald 
4. B.M.R.C. 
8. Sorensen 
10. Ritland 
13. Breddin 
14. Smith 
15. ASPECT 
Anticoagulated Reference 
group group 
0/119 !IllS 
21145 1lI170 
3/195 lI188 
2/139 6/95 
0/102 lII06 
lI320 lI309 
20/607 441607 
37/1700 6211704 
Individual RR 
(95% CI) 
0.21 (0.05-0.95) 
2.89 (0.30-27.6) 
0.23 (0.05-1.10) 
0.97 (0.06·15.4) 
0.45 (0.27-0.76) 
0.60 (0.40·0.89) 
RR: Relative Risk, CI: Confidence Interval, --: not available 
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Table 7. Cumulative relative risk of stroke· in the presence of long-term oral 
anticoagulant therapy in hospital survivors of myocardial infarction. 
Study 
No. 
Prospective studies Randomised trials Randomised, Double-blind 
Placebo-controlled trials 
__ w_w_.w _______________________________________________________________________________________________________________________ ._. ___ • 
RR (95% CI) RR (95% CI) RR (95% CI) 
I. Bjerkelund 
3. Harvald 0.19 (0.05-0.72) 
4. B.M.R.C. 0.42 (0.15-1.15) 
8. Sorensen 0.35 (0.15-0.79) 
10. Ritland 0.33 (0.15-0.75) 1.47 (0.25-8.82) 
13. Breddin 0.36 (0.17-0.79) 1.30 (0.29-5.83) 
14. Smith 0.43 (0.28-0.65) 0.51 (0.32-0.82) 
15. ASPECT 0.51 (0.38-0.68) 0.56 (0.41-0.76) 0.54 (0.39-0.73) 
--------------------------------------------------------------------------------------------------------------------------------_.--.. 
RR: Relative Risk; CI: Confidence Interval, -- indicates the first available study for analysis 
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1064 (433) 
1964 (619) 
1967 (869) 
1969 (1604) 
1989 (1742) 
1969 (1960) 
1989 (2126) 
1974 (2386) 
1980 (3016) 
1990 (4229) 
1994 (7633) 
0.5 1 2 
Figure 1. Cumulative relative mortality risk after myocardial infarction in the 
presence of oral anticoagulant treatment. The years of publication of randomised 
trials are depicted and the cumulative number of patients is shown between 
brackets. 
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AntlOO&QulanU bttter Reftt0n08 better 
1984 (43S) 
1984 (519) 
1981 (889) 
1989 (1804) 
1989 (1142) 
1989 (1960) 
1980 (2679) 
1990 (3193) ->-
1994 (7197] -+-
0.6 1 2 
Figure 2. Cumulative risk of recurrence after myocardial infarction in the 
presence of oral anticoagulant treatment. The years of publication of randomised 
trials are depicted and the cumulative number of patients is shown between 
brackets. 
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1969 (206( 
1960 (837] 
1990 (20611 , 
1994 (64651 --<-
, , 
0.25 0.5 2 4 8 
Figure 3. Cumulative relative risk of stroke after myocardial infarction in the 
presence of oral anticoagulant treatment. The years of publication of randomised 
trials are depicted and the cumulative number of patients is shown between 
brackets. 
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Discussion 
This meta-analysis provides evidence for a 10% reduction in total mortality by 
anticoagulant treatment after myocardial infarction, a 43 % reduction in fatal and 
non-fatal recurrent myocardial infarctions and a 45 % reduction in cerebro-vascular 
events in randomised trials. Statistical significance for prevention of mortality has 
been established in 1994 while efficacy for prevention of reinfarction was 
established in 1964 and for prevention of stroke in 1990. The meta-analyses that 
included studies with a non-randomised design or that were restricted to trials with 
a double-blind design showed similar results. 
Although a cumulative meta-analysis of clinical trials has an advantage over 
standard meta-analysis in that it shows the temporal compilation of evidence with 
respect to a typical treatment effect, it has the same flaws as any meta-analysis. 
Results may be affected by selection bias,"·30 as well as by the methodology of 
selected studies.'l.n and in this particular case, the quality of treatment. The 
current selection criteria have therefore been defined upfront and the studies that 
were considered not eligible for analysis have been listed. Also, the studies that 
were included in the present meta-analysis were clustered according to 
methodology. Interestingly, the summarised effect estimates of anticoagulant 
therapy on mortality and recurrent myocardial infarction in the various sets of 
studies showed only small differences. It should be noted however that 90% of 
patients of prospective studies participated in randomised trials. 
The 10% mortality reduction in the present analysis differs from previous 
meta-analyses, that usually reported higher mortality reductions. The International 
Anticoagulant Review Group was the first to pool data from several studies. 27 
Results in 2,487 patients from nine studies, four of which were not randomised, 
were confined to improved survival during the first years after myocardial 
infarction in males with a history of angina pectoris. Following the publication of a 
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number of small to moderately sized trials, a pooled analysis of seven randomised 
trials in 1983 reported a 28 % mortality reduction and a 45 % reduction in recurrent 
myocardial infarction." Trials that involved patients using low dose anticoagulant 
therapy as a reference group were excluded in that analysis. A recent paper on 
meta-analyses of different treatments after myocardial infarction also reported a 
higher mortality reduction but differed from the present analysis because it included 
the Sixty Plus tria!." Finally, the large contribution (45% of the patients) by the 
recently conducted ASPECT trial that showed only a 10% reduction in mortality 
may also have attributed to the disparity in mortality reductions with previous 
meta-analyses. However, as clearly shown in the tables, exclusion of this trial 
would only affect the confidence intervals but not the effect estimate of the 
combined results. We therefore assume that the differences in results of various 
reports has resulted to a large extent from the selection of studies. 
In summary, we conclude that this cumulative meta-analysis provides evidence 
for a substantial and consistent reduction in recurrent myocardial infarction, a 
substantial reduction in cerebro-vascular stroke and a moderate but significant 
reduction in mortality by long-term anticoagulant therapy in post myocardial 
infarction patients. 
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Characteristics and prognosis of non-participants of a 
multi-centre trial of long-term anticoagulant therapy 
after myocardial infarction 
Chapter 5 
Abstract 
Participants of a randomised trial may differ from eligible non-participants as a 
result of selection. We studied the distribution of prognostic factors and survival in 
eligible patients of a multi-centre trial of long-term oral anticoagulant treatment 
after myocardial infarction. 
All hospital survivors of myocardial infarction in one participating clinical centre 
of a multi-centre, randomised, double-blind, placebo-controlled trial of long-term 
anticoagulant treatment after myocardial infarction were screened for entry criteria. 
Subsequently, prognostic factors and survival of participants were compared with 
eligible but not randomised patients. 
The 350 participants were younger and were more often of male gender and 
more often smokers compared with 587 non-participants. Non-participants had 
more frequently suffered a previous myocardial infarction and were treated more 
often with diuretics and ACE-inhibitors, suggesting a higher proportion of patients 
with chronic heart failure in this group. Age, previous myocardial infarction and 
the use of diuretics at discharge were independent predictors of mortality, consent 
showed no association. 
Our findings indicate that participants of a clinical trial have a better prognosis 
during the first years following myocardial infarction compared to eligible non-
participants as a result of a higher prevalence of cardiovascular riskfactors 
associated with mortality in the non-participants. 
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Introduction 
If only a proportion of eligible patients is enroled in a trial, the distribution of risk 
factors and prognosis in the study population may not be similar to 
non-participants.'" Although the features of the study population may be well 
described by the entry criteria of the trial, some unforseen or unknown factors may 
lead to differences in the distribution of riskfactors between participants and 
non-participants.'" Knowledge of dissimilarities in the distribution of riskfactors in 
the population of participants and non-participants may therefore help to evaluate 
possible sources of bias and elucidate the generalis ability of the effects of treatment 
as observed in the trial. In this study we have compared prognostic factors and 
survival of participants and non-participants from two primary referral hospitals 
that took part in a large, randomised, double-blind, placebo-controlled trial of the 
efficacy of long-term oral anticoagulant treatment after myocardial infarction. 
Methods 
Data of participants were obtained from the Dutch 'Anticoagulation in the Secon-
dary Prevention of Events in Coronary Thrombosis (ASPECT) trial. 6 Between 
September 1986 and January 1992, 3,404 myocardial infarction sUlvivors were 
recnlited by 60 hospitals and randomised to oral anticoagulant treatment or 
matching placebo following their hospital discharge. Subjects were followed for a 
median period of 37 months at one of 19 participating thrombosis centres, 
specialised in the computerised monitoring of oral anticoagulant therapy. Trial 
medication was continued until the end of the trial follow-up, on June 30, 1992. 
Results of the trial were as follows: death occurred in 170 of the 1,700 
anticoagulated patients as compared to 189 of the 1,704 placebo patients, a 
reduction of 10% (95% Confidence Interval -11 to 27%). Recurrent myocardial 
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infarction was observed in 114 anticoagulated patients versus 242 placebo patients, 
a reduction of 53 % (41 to 62 %) and cerebro-vascular event in 37 anticoagulated 
patients versus 62 placebo patients, a reduction of 40% (10 to 60%). Major 
bleeding complications were seen in 73 anticoagulated and in 19 placebo patients. 
For the present comparison one participating clinical institution in Enschede was 
selected. This centre commenced participation on April 1, 1987 and continued 
patient enrollment until December 31, 1991 when the trial was ended. Following 
completion of the trial, the medical registration department of the centre was asked 
to identify all patients who were discharged alive with the clinical diagnosis 
'myocardial infarction' (International Code of Disease 410, 9th version) during the 
intake period of the trial. Identified patients were then screened for entry criteria of 
the ASPECT trial, i.e. proven myocardial infarction with creatine kinase levels 
exceeding twice the upper reference level. Patients were subsequently screened for 
the presence of exclusion criteria, i.e. anticoagulant treatment on admission, 
residency outside the trial area, left ventricular dyskinesia or aneurysm on echocar-
diography or angiography, anticipated revascularisation procedure, indication or 
contra-indication for oral anticoagulant therapy, malignant disease with poor 
prognosis and mental disorder. 
The following data were collected from medical records of selected patients: 
age, gender, history of previous myocardial infarction, administration of 
thrombolytic agents, highest Killip class during admission, third degree A V-block, 
discharge medication (diuretics, Jl-blockers and ACE-inhibitors), antithrombotic 
medication at discharge (oral anticoagulants and aspirin), as well as risk factors for 
cardiovascular disease (current smoking, diabetes, history of hypertension, family 
history of coronary disease). If available, results of echocardiography and an-
giography during admission were collected for the assessment of ventricular 
function and coronary anatomy. Results of echocardiography were considered until 
6 weeks after discharge if echocardiography was not performed during admission. 
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For all patients vital status was determined at the end of the follow-up of the trial 
on June 30, 1992. 
Data analysis 
For comparison of discrete data between groups the chi-square test was used. 
Unpaired t-test was employed for continuous variables. Clinical variables such as 
age, gender, the use of thrombolytics, ACE-inhibitors, diuretics, ll-blokkers, and 
trial participation and cardiovascular riskfactors such as smoking, previous 
myocardial infarction, Killip class > I and hypertension were inserted in a Cox 
proportional-hazards model to assess their independent association with mortality. 
Results 
Between April I, 1987 and December 31, 1991, 2,072 patients were discharged 
after admission for acute myocardial infarction. Of these, 350 were enrolled in the 
trial. Of the remaining 1,722 patients, 1,135 patients were not considered eligible 
for reasons listed in Table I. Most patients were excluded because of residency 
outside the trial region. Other frequent reasons for exclusions were the use of 
anticoagulants on admission and a diagnosis of myocardial infarction that did not 
satisfy the selection criteria. The remaining 587 patients constituted the group of 
eligible but not randomised patients that was compared to the 350 participants. 
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Table 1 Reasons for exclusion of enrolment in the ASPECT trial 
Patients discharged alive after lUI 
Randomised in ASPECT 
Available (%) 
Reasons for non eligibility: 
- Residence outside the study region (%) 
- Anticipated revascularisation (%) 
- CK < 2 fold increase (%) 
- Anticoagulant treatment on admission (%) 
- Contraindication for OAC (%) 
- Indication for OAC (%) 
- Dyskinesia or aneurysm (%) 
- Carcinoma (%) 
- Mental disorder (%) 
- Missing data (%) 
Nwnber of eligible but not randomised patients 
CK, creatine kinase, GAe, oral anticoagulants 
2072 
350 
1722 
302 
107 
257 
231 
31 
29 
81 
7 
22 
68 
587 
(100.0) 
(17.5) 
( 6.2) 
(14.9) 
(13.4) 
( 1.8) 
( 1.7) 
( 4.7) 
( 0.4) 
( 1.3) 
( 3.9) 
(33.4) 
Characteristics of the non-participants and participants are given in Table 2. On 
average, non-participants were significantly older and more often of female gender 
and more of them had sustained a previous myocardial infarction. In addition, 
fewer of the non-participants smoked cigarettes while diuretics and ACE-inhibitors 
were more frequently prescribed at discharge. 
Mortality was significantly higher in non-participants than in participants. At the 
end of follow-up mortality amounted to 12% in participants and 20% in non-
participants. Crude survival curves of participants and non-participants are 
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presented in Figure 1. 
100% 
PARTICIPANTS 
90% 
80% 
70% NON-PARTICIPANTS 
60% 
60% L-------__ --------.---------r-------__ --------, 
o 1 2 3 4 5 
YEARS 
Figure 1. Survival in participants and non-participants. 
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Table 2 Characteristics at baseline of participants and non-participants 
Variable non-participants participants 
Number of patients 587 350 
Age, mean yr ± SO 64 59 <0.0001 
Male 63.5 83.4 <0.0001 
Previous MI 12.4 8,3 0.048 
Killip > 1 30.5 33.7 0.28 
Total A V -block 5.5 3.7 0.229 
Risk factors 
Current smoking 44.8 58.9 <0.0001 
Fam. history 4.9 6.3 0.380 
Diabetes 10.1 8.6 0.455 
Hypertension 20.6 19.7 0.741 
Thrombolysis 29.1 32.6 0.245 
Medication at discharge 
Diuretics 34.8 16.8 <0.0001 
ACE inhibitors 17.4 10.6 <0.005 
Beta-blockers 39.0 36.3 0.406 
Anticoagulants 76.5 50.0 <0.0001 
ASA 8.2 
Ecbocardiography performed 63.0 56.9 0.061 
EDY> 55 mm 24.6 17.6 0.055 
Akinesia 80.8 79.5 0.854 
LV angiography performed 12.8 10.6 0.314 
EDY> 55mm 5.3 8.1 0.568 
Akinesia 82.7 83.8 0.882 
Coronary angiography performed 14.1 11.1 0.187 
One vessel disease 59.0 53.8 0.589 
Two vessel disease 25.3 33.3 0.356 
Three vessel disease 9.6 10.3 0.915 
AC: Anticoagulants, ASA: Aspirin 
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Because prognosis of both patient groups was determined by similar clinical 
variables and cardiovascular risk factors, a multivariate Cox analysis was per-
formed in the combined population with trial participation as a covariate. The 
results of this analysis are presented in Table 3. After adjustment for the other 
prognostic factors, participation in the trial was no longer independently associated 
with improved outcome. Survival of patients in strata defined by age and use of 
diuretics are shown in Figure 2 and 3; the curves illustrate that survival in par-
ticipants and non-participants is comparable in the various strata. 
Table 3. Relative risk (and 95% confidence intervals) of factors associated with mortality 
RR (95% el) 
Age (increment of 1 year) 1.04 (1.03,1.06) 
Diuretics 2.10 (1.46,2.97) 
Diabetes 1.95 (0.26,2.94) 
Previous MI 1.60 (1.07,2.40) 
Thrombolysis 0.44 (0.25,0.76) 
Beta Dlockers 0.60 (0 .. 40,0.90) 
Non participation 1.07 (0.72,1.61) 
RR: Relative Risk. CI: Confidence Interval 
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Figure 2. Survival according to age. Straight lines indicate participants, dotted 
lines indicate non·participants. 
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Figure 3. Survival according to the use of diuretics. Straight lines indicate par-
ticipants, dotted lines indicate non-participants. 
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Discussion 
This analysis demonstrates that participants of our multi-centre trial differed 
significantly from eligible non-participants with respect to important prognostic 
factors and, subsequently, survival. Higher age and the higher prevalence of 
clinical variables associated with left ventricular dysfunction such as previous 
myocardial infarction and the use of medication proved explanatory for the 
impaired prognosis of non-participants during the first years following myocardial 
infarction. 
Despite the potentially important implications of disparities between participants 
and non-participants of a trial, only few trials have previously supplied data in 
sufficient detail to allow such a comparison.' Recently, the investigators of the 
Warfarin Re-infarction Study explored the demographical and clinical variables of 
non-participants. 8.' In agreement with our findings, the authors demonstrated that 
higher age, female gender, previous myocardial infarction and the use of diuretics 
was more frequently present in non-participants. However, in contrast with our 
findings only age was found to be associated with mortality whereas our data 
indicate that previous myocardial infarction and the use of diuretics also indepen-
dently predicted death. to Also, stratification according to these variables in our trial 
generally counterbalanced the disparity in mortality between participants and non-
participants, suggesting that non-cardiovascular comorbidity had contributed only 
little to the difference in prognosis between these patient groups." 
Although reasons for non-participation of a trial may vary and be quite personal, 
including poor motivation, low mobility and saturation with focusing on disease,'·12 
the high proportion of non-participants who were discharged with oral anticoagu-
lants (80%) in this trial clearly shows that refusal to participate was not based on 
ineligibility for anticoagulant treatment. The higher proportion of patients among 
non-participants with enlarged left ventricles on echocardiography illustrates the 
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higher prevalence of left ventricular dysfunction that may have partly resulted from 
the higher incidence of previous myocardial infarction. These data suggest that the 
higher risk of mortality during the early years after myocardial infarction of non-
participants is largely related to complications associated with chronic heart 
failure." 
Our analysis is constrained by a few limitations. For practical reasons we have 
restricted this investigation to only one of the participating clinical centres. Also, 
due to the particular organisation of Dutch thrombosis centres in many different 
regions, patients who resided outside the region had to be excluded for analysis. 
The influence of these restraints cannot be quantitated. However, the selected 
centre represented the only clinical centre in the district of this particular throm-
bosis centre and had a primary referral function for the region. As the prognosis of 
participants from this hospital was similar to that of other participants of the 
ASPECT trial, it seems reasonable to assume that the results of this analysis are 
representative for the general post myocardial infarction population. 
In summary, this analysis suggests that differences in the distribution of car-
diovascular risk factors associated with impaired left ventricular function account 
almost entirely for the differences in prognosis between participants and non-par-
ticipants of a trial in post myocardial infarction patients during the first years 
following acute myocardial infarction. 
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Abstract 
Although the costs associated with monitoring are often mentioned as a major 
drawback of this mode of therapy, to date no attempts have been made to estimate 
the costs of long-term anticoagulant treatment relative to its benefits. 
We have performed cost-effectiveness analysis, based on the costs of hospital stay 
during readmissions, costs related to major cardiological interventions and costs of 
oral anticoagulant treatment. 
The costs of oral anticoagulant treatment were estimated at Dfl. 394 per patient 
year. Placebo patients stayed 18,830 days in the hospital as compared to 15,083 
days for anticoagulated patients. Average costs per patient of medical care during 
follow-up were estimated at Dfl. 10,784 for placebo patients and Dfl. 9,878 for 
anticoagulated patients. 
It is concluded that costs of long-term oral anticoagulant treatment after myocar-
dial infarction are outweighed by the costs of prevented clinical events. 
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Introduction 
The efficacy of long-term oral anticoagulant treatment in hospital survivors of 
myocardial infarction has recently been investigated in two randomised, double-
blind, placebo-controlled trials. Both trials demonstrated a substantial reduction in 
cardiovascular complications after myocardial infarction as a result of protracted 
anticoagulant therapy.,,2 However, long-term anticoagulant treatment is also 
associated with distinct disadvantages. First, patients on anticoagulant treatment 
have an increased risk of major bleeding, the incidence of which is estimated at 1 
to 3 events per 100 patient-years of treatment.'" Second, to maintain the patient's 
prothrombin time within the target mnge, oral anticoagulant treatment requires 
regular monitoring to adjust dosage of anticoagulants individually.' Although the 
costs associated with monitoring are often mentioned as a major drawback of this 
mode of therapy, to date no attempts have been made to estimate the costs of long-
term anticoagulant treatment relative to its benefits. 
Based on the data from the recent Anticoagulation in the Secondary Prevention of 
Events in Coronary Thrombosis (ASPECT) trial, we have calculated costs and 
benefits of long-term anticoagulant treatment in post myocardial infarction patients 
from the societal perspective. 
Methods 
Study Population 
Results of the randomised, double-blind, placebo-controlled ASPECT trial have 
been reported elsewhere.2 In short, between September 1986 and January 1992, 
3,404 survivors of myocardial infarction were selected from 60 Dutch hospitals for 
randomisation after a median of 4 days of discharge to oml anticoagulant therapy 
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or matching placebo. Patients were followed for a mean period of 37 months at one 
of 19 participating outpatient clinics (thrombosis centres), specialized in the com-
puterized monitoring of oral anticoagulant treatment. No patient was lost to follow-
up. The major clinical outcome events were as follows: death occurred in 170 of 
the 1,700 anticoagulated patients and in 189 of the 1,704 placebo patients, a 
reduction of 10% (95% confidence interval -11 to 27%). Recurrent myocardial 
infarction was observed in 114 anticoagulated patients versus 242 placebo patients, 
a reduction of 53% (41 to 62%), and cerebro-vascular events in 37 anticoagulated 
patients versus 62 placebo patients, a reduction of 40% (10 to 60%). Major 
bleeding complications were seen in 73 anticoagulated and 19 placebo patients 
(relative risk 3.9,95% confidence interval 2.3 to 6.4) 
Assessment of medical care 
The present analysis is based on the assessment of all actually observed days of 
hospitalization and the number of the following interventions: angiography, an-
gioplasty, coronary bypass surgery, the use of thrombolytic agents and oral 
anticoagulant treatment. Data from hospital admissions during follow-up were 
obtained from the medical records. All events were blindly classified by the 
Morbidity and Mortality Classification Committee. Medical care was subdivided 
into care for vascular events, that are likely to be affected by anticoagulant 
treatment, and non-vascular events. The vascular events considered here are: 
recurrent myocardial infarction (and the use of thrombolytic agents), unstable 
angina pectoris, cardiological interventions (i.e. angiography, angioplasty and 
coronary bypass surgery), stroke, bleeding complications and arterial or venous 
thrombo-embolism. 
Non-vascular events included hospital admissions for various reasons ranging from 
pneumonia to elective surgery. No costs were assigned to fatal events that occurred 
outside the hospital. Indirect costs for patient time and out-of-pocket costs for 
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patients were not included. 
Calculation of costs of hospital care 
The number of events and medical care as observed in the trial were multiplied 
with the estimates of unit costs. Unit costs of hospital care were calculated 
following the guidelines of the Dutch Ministry of Health in 1993 on costs of health 
care programmes, which include all costs of hospitalization, i.e. hotel, overhead 
and medical care costs. The costs of one day in hospital was estimated at Dfl. 773 
per day, irrespective of the intensity of care provided, except for costs of additional 
cardiologic interventions.' In addition, costs of cardiologic interventions were 
estimated on the basis of a weighted average of published unit costs estimates in 
Dutch hospitals, i.e. Dfl. 3,000 for angiography, Dfl. 5,000 for angioplasty and 
Dfl. 20,000 for coronary bypass surgery which were appended to the costs 
associated with the hospitalization.' Costs of thrombolytic agents (75% strep-
tokinase, 25 % r-tPA) administered during hospital admissions were estimated at 
Dfl. 500. 
Costs of alllicoagulant treatment 
Costs of oral anticoagulant treatment were calculated from the average rates of 
monitoring by thrombosis centres in the Netherlands and the costs of anticoagulant 
medication in 1990. These costs include all procedures of monitoring i.e. getting 
test results to the patient and advising the patient to adjust the anticoagulant dose. 
With 17.3 visits on average per year for monitoring and average costs of Dfl. 
12.65 per visit, a total cost of Dfl. 219 per patient-year was adopted. Additionally, 
costs of the anticoagulant dmg supply were estimated at Dfl. 175 per patient-year. 
Consequently, total costs for anticoagulant treatment including monitoring and drug 
supply amounted to Dfl. 394 per patient-year. 
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Results 
Patients in both treatment groups were similar with respect to characteristics at 
baseline (Table I). The number of patients with evidence of impaired left 
ventricular function such as previous myocardial infarction and high Killip class 
was low. 
Table 1. Baseline characteristics of the randomised patients, according to assigned 
therapy. 
Anticoagulation Placebo patients 
Number of patients 1700 1704 
Mean age (yr ±SD) 61 (± 11) 61 (± 11) 
Male (%) 81 79 
Previous myocardial infarction (%) 9 9 
Diabetes mellitus (%) 8 7 
Thrombolytic agents used (%) 25 25 
Aspirin during admission (%) 28 28 
Killip class 111 or IV (%)" 5 5 
B~Blocking agents at discharge (%) 51 51 
'" Highest Killip or MIRU class reached in hospital. 
Reasons for hospital admissions are shown in Table 2. After a mean follow-up of 
37 months, placebo patients had spent 3,747 more days in hospital as compared to 
anticoagulated patients. The largest difference in hospital stay between the groups, 
2,056 days, resulted from admissions for acute myocardial infarction. The second 
largest difference, 1,002 days, resulted from admissions for unstable angina. The 
mean period of hospital stay for the different categories of admissions was very 
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similar in both patient groups. Placebo patients more often underwent emergency 
angiography and angioplasty (Table 2). Days of hospitalization related to emergen-
cy interventions are not presented because they are incorporated in the hospital stay 
of the associated event. Hospital days associated with bleeding included all 
extra-cranial bleeding complications leading to hospital admission, while hospital 
days related to intra-cranial bleeding complications are included in those concerning 
stroke. 
Table 2. Hospital admissions and associated hospital stay ("intention-to-treat" analysis) 
Anticoagulation Placebo 
Number of patients 1,700 1,704 
Palient~years of follow-up 5,241 5,200 
no. of events (total number of days in hospital) 
Vascular events: 
Recurrent MI 110 (1,556) 255 (3,612) 
Thrombolysis 25 74 
Unstable angina 216 (2,498) 267 (3,500) 
Angiography 
Elective 260 (1,008) 293 (1,074) 
Emergency 80 147 
Angioplasly 
Elective 53 (312) 52 (286) 
Emergency 18 42 
Bypass surgery 
Elective 89 (1,638) 100 (1,652) 
Emergency 39 42 
Cerebra-vascular event 33 (752) 49 (1,080) 
Bleeding 64 (737) 21 (224) 
Arterial or venous thromboembolism 15 (178) 23 (363) 
Non vascular events 484 (6,404) 521 (7,039) 
Total (15,083) (18,830) 
MI, myocardial infarction, ( ) total number of hospital days. 
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The cumulative number of days in the hospital regardless of the reason for 
admission for both groups according to the assigned treatment is presented in 
Figure 1. Total costs are shown in Table 3. Costs have also been discounted at 
5%. 
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Figure 1. Cumulative number of days in Ihe hospital, according to assigned 
therapy. 
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Table 3. Costs of medical treatment per treatment group 
Vascular events: 
Recurrent M1 
Thrombolysis 
Unstable angina pectoris 
Angiography 
Angioplasty 
Bypass surgery 
Cerebro-vascular event 
Bleeding 
Arterial or venous thromboembolism 
Non-vascular events 
Anticoagulant treatment 
Total 
Average costs per patient 
Discounted at 5 % 
Anticoagulation 
1,202,788 
12.500 
1,930,954 
1,799,184 
596,176 
3,826,174 
581,296 
569,701 
137,594 
4,950,292 
2,064,954 
17,671,613 
10,395 
9,878 
Placebo 
2,792,076 
37,000 
2,705,500 
2,150,202 
691,078 
4,116,996 
834,840 
173,152 
280,599 
5,441,147 
19,222,590 
11,281 
10,784 
MIj myocardial infarction, costs expressed in Dutch guilders, 1 USD= 1.80 Dfl. 
Cost-effectiveness 
The highest disparity in costs of medical care in favour of anticoagulated patients 
was the result of the higher number of admissions for recurrent myocardial 
infarction in placebo patients. The highest single contribution in costs of interven-
tions for vascular events was due to coronary bypass surgery in both patient 
groups. 
The total discounted costs for medical care of anticoagulated patients was Dfl. 
1,584,093 lower than costs for medical care of placebo patients. Anticoagulant 
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treatment was associated with 220 (37 %) fewer admissions for thrombo-embolic 
complications and 43 (200%) more admissions for bleeding complications as 
compared to placebo. Average medical costs during follow-up for anticoagulant 
patients were Oft. 886 lower than for placebo patients. When costs are discounted 
at 5 % per year the expected savings are estimated at Oft. 896. 
Sensitivity analysis 
To examine whether reasonable variations in our assumptions would seriously 
affect the calculations, we analyzed how changes in costs of baseline variables 
would affect the principal outcome. The results of changes in costs of each distinct 
variable are presented in Table 4. This table shows that the largest effect on 
average costs of medical care would result from variations in the costs of 
hospitalization if costs of interventions and anticoagulation were unchanged. It also 
indicates that reduction of the costs of hospital stay would minimize the economic 
benefit of anticoagulation. If we would assume an average hospital stay of 7 days 
for unstable angina pectoris and recurrent myocardial infarction (instead of the 
number observed in the trial of 13 and 14 days, respectively), the benefit in 
average costs of anticoagulated patients would decrease to Oft. 123, nonetheless 
still in favour of anticoagulation. All other variations in costs of contributing 
variables, including costs of anticoagulant treatment, would only marginally affect 
the average costs. 
Changes in costs of anticoagulant treatment would affect average costs of medical 
care less than changes in costs of bypass surgery. The average costs of medical 
treatment would only become equal if billing figures of anticoagulant treatment 
would almost double to Oft. 690 per patient year. 
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Table 4. Effect on discounted average costs of medical care by changes of the baseline variables by - and + 30% 
Anticoagulation Placebo 
Discounted average costs in this analysis 9,878 10,784 
Estimation of average costs of medical care per patient if each individual variable would vary 30% around the projected costs. 
Variable Number New average costs Number New average costs 
( -30% ) ( +30% ) ( -30% ) ( +30% ) 
Hospital days (Dfl. 773) 15,083 (7,933 ) ( 11,823 ) 18,830 ( 8,364) ( 13,204) 
Angiography (Dfl. 3,000) 340 (9,698 ) ( 10,058) 440 ( 10,552) ( 11,017) 
Angioplasty (Dfl. 5,000) 71 (9,815 ) ( 9,940) 94 ( 10,701 ) ( 10,867) 
Bypass surgery (Dfl. 20,000) 128 (9,426 ) ( 10,330) 142 ( 10,284 ) ( 11,284) 
Anticoagulant treatment (Dfl. 394/year) 5,241 (9,554 ) ( 10,201 ) 
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Discussion 
When the merits of long-term oral anticoagulant treatment are discussed, high costs 
of treatment are usually mentioned among the drawbacks inhibiting its large scale 
application. Our data not only indicate that this notion should be rejected but also 
that anticoagulant treatment during a mean period of three years after myocardial 
infarction would save approximately Dfl. 896, equivalent to approximately 519 
USD, per patient compared to placebo. The largest contribution to the savings in 
costs of medical care associated with anticoagulant treatment resulted from the 
substantial reduction in the rate of recurrent myocardial infarction and related 
cardiological interventions. 
Since the costs associated with hospitalization contribute the most to the total 
costs, variations in costs of hospital stay would have the most marked influence on 
the disparity in medical costs between anticoagulated and placebo patients. Never-
theless, even if the average hospital stay for coronary thrombo-ischaemic events 
were halved (or anticoagulant treatment would be half as efficacious in the preven-
tion of these events), the economic benefit of anticoagulation would still remain. 
Moreover, it should be noted that this analysis did not consider costs of con-
comitant medication in ambulant patients and indirect costs, such as absence from 
work. Since these costs are likely to be positively related to the number of hospital 
admissions, their consideration would probably further augment costs in placebo 
patients. 
The costs of anticoagulant treatment in this analysis are based on the Dutch 
situation where monitoring of long-term anticoagulant treatment of outpatients is 
executed through a unique and efficient network of specialized thrombosis centres. 
Billing levels for anticoagulant treatment may therefore differ quite substantially 
from other countries such as the United States. However, costs of other forms of 
medical care are likely to be equally more expensive. For example, costs of 
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angioplasty in the United States have recently been estimated at USD 9,000, about 
three times the unit costs in Holland. If we assume all costs of medical care 
(including costs of anticoagulant treatment) in the United States to be double of 
those in Holland, the savings by anticoagulant treatment would also double. The 
sensitivity analysis illustrates the effect on total costs if the estimated costs of any 
individual variable would differ considerably fro the true costs. Even so, costs of 
anticoagulant treatment could almost be doubled in the present analysis before a 
break-even point in medical costs for both patient groups was reached. 
This cost-effectiveness analysis of long-term anticoagulant treatment compares 
favourably to other interventions for myocardial infarction, usually presented as 
costs estimates per year of life gained. g· 1O As recent improvements in the medical 
care of myocardial infarction have improved long-term sUlvival, II·" non-fatal 
events following myocardial infarction will constitute a larger proportion of 
medical costs in future health care. Our analysis shows that application of an-
ticoagulant treatment even in a low risk population of post myocardial infarction 
patients with only a moderate incidence of non-fatal thrombo-embolic complications 
will provide economic benefit. 
Despite these transparent results, the implications of this analysis for clinical 
practice are constrained as the costs and effects of anticoagulant treatment are not 
compared to alternative antithrombotic drugs such as aspirin. Aspirin has also been 
shown to reduce thrombo-embolic events after myocardial infarction, although 
possibly not as efficacious as coumarins, without the need for monitoring. ".Il A 
proper evaluation of the economic aspects requires a direct comparison between 
both therapies. Awaiting the results of such a comparison of treatment strategies, 
we conclude that long-term oral anticoagulant treatment is cost-effective for the 
prevention of cardiovascular complications after myocardial infarction. 
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General discussion 
The ASPECT trial has demonstrated that long-term anticoagulant treatment after 
myocardial infarction very effectively reduces the incidence of arterial thrombo-
embolic events. The moderate effect of oral anticoagulant treatment on mortality 
can best be explained by examining the contributing causes of vascular death in the 
trial (chapter 2). The majority of deaths in both groups have been categorized as 
being either sudden/instantaneous, unobserved/unexpected (which are also most 
likely to be sudden in onset) or due to congestive heartfailure. As these conditions 
are more likely to be the result of electrical instability and end-stage ischemia as 
the result of coronary heari disease rather than coronary thrombosis, anticoagulant 
treatment would not be expected to yield any effect on these endpoints. As 
suggested in chapter 2, an additional plausible explanation for the modest reduction 
in mortality would lie in the improved treatment of acute myocardial infarction 
over the last years leading to a reduced fatality rate. 
Although a reduction of coronary thrombotic events by the use of coumarin 
derivatives could be anticipated in the light of the pathogenesis of arterial sclerosis 
and coronary thrombosis, most of the trials that have been conducted in the past to 
investigate the effect of anticoagulant treatment in hospital survivors of myocardial 
infarction failed to show conclusive results. As demonstrated in chapter 4, this 
inability to provide unequivocal results in individual trials predominantly resulted 
from insufficient sample sizes. Since the statistical power of a trial largely depends 
on the number of endpoints, most trials were by definition inadequate in size or 
follow-up to show the true effect of long-term oral anticoagulant treatment. 
Combination of all available data according to predefined selection criteria cor-
roborated the results of the ASPECT trial. As demonstrated in chapter 5, patients 
selected for the ASPECT trial differed favourably with respect to the presence of 
adverse prognostic factors relative to patients who met all the criteria for the trial 
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but were not randomised. This analysis suggests that selection bias has occurred in 
the ASPECT trial, favouring patients with better prognosis to participate. A higher 
participation of patients with impaired prognosis in our trial might have resulted in 
an higher prevalence of unfavourable prognostic factors, such as previous 
myocardial infarction, and presumably also in an higher incidence of clinical 
events. As a consequence, the incidence density rates of the ASPECT trial would 
probably resemble much closer those of the W ARIS trial. However, the investi-
gators of the W ARIS trial provided evidence that their population too differed 
favourably from the general eligible population with respect to mortality, 1 which 
makes it impossible to speculate about the effect of selection on the number of 
clinical endpoints in both trials. 
An important clinical consideration concerns the identification of patients in 
whom the effect of long-term oral anticoagulant treatment is less or absent. In 
chapter 3 data have been presented that indicate that women and diabetics have 
only limited benefit of treatment. The presence of diabetes mellitus has previously 
been shown to interact with the effects of oral anticoagulant treatment in a 
subgroup analysis of the W ARIS trial.2 Although the results of subgroup analyses 
should be viewed with caution, the confirmation of this finding in two separate 
analyses certainly warrants careful consideration before prescribing long-term oral 
anticoagulant treatment to this particular category of patients. However, more data 
are needed to substantiate this finding since statistical tests failed to provide 
evidence of interaction in either subgroup. We have also provided data to suggest 
that prior myocardial infarction, higher age and the administration of thrombolytic 
agents during the acute phase of myocardial infarction are independent predictors 
of cardiovascular complications during follow-up and can therefore identify a 
subset of patients who may have more benefit from oral anticoagulant treatment. 
Although the presently available data suggest that administration of anticoagulant 
treatment after myocardial infarction has a profound effect on the occurrence of 
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major clinical events, this mode of therapy is practically constrained as a result of 
the need of monitoring. While the acceptability of the burden of this pracedure is 
largely and mostly a personal matter, the associated costs are an issue of concern to 
the society at large. It is therefore important to be informed on the costs and 
benefits of long-term oral anticoagulant treatment. Our data indicate that application 
of long-term oral anticoagulant treatment cuts total costs of medical care as 
compared to placebo treatment. This remarkable result is mainly due to a large 
reduction in coronary thrombo-ischemic events and associated hospital stay in 
anticoagulated patients. As our population comprised low-risk patients with a 
consequently low incidence of thrambo-embolic complications and mortality, it may 
be speculated that selection of patients who are at higher risk of thrambo-embolic 
complications would even further improve the cost-effect ratio of anticoagulant 
therapy. 
In summary, our findings support the conclusion that long-term oral an-
ticoagulant therapy after myocardial infarction is associated with a substantial and 
clinically relevant reduction of thrombo-embolic complications in low risk patients, 
that the magnitude of this effect is not modified in subgroups of clinically defined 
post myocardial infarction patients, perhaps with the exception of diabetics, and 
that this type of therapy is cost effective relative to placebo during the early years 
after myocardial infarction. 
Further research 
The conclusions given above are restricted to the effect of oral anticoagulant 
treatment compared to placebo. The favourable effects of aspirin in acute ischaemic 
heart disease in previous studies have formed a rational for its administration 
during the acute phase of myocardial infarction.'-' Recent clinical trials have also 
pointed to a beneficial effect of antiplatelet drugs beyond the acute phase of 
ischaemic heart disease. 6•7 The common pathogenesis of unstable angina pectoris 
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and myocardial infarction has facilitated the application of aspirin for both in-
dications. During coronary thrombosis, both activation of thrombin and platelets 
occur.' Subsequent coronary artery thrombi vary in composition from predominant-
ly platelet aggregates in the vessel wall to mainly fibrin accumulation in the lumen. 
A recent study concluded that fibrin formation and platelet activation are probably 
equally important in the early hours of myocardial infarction.9 Aspirin irreversibly 
acetylates platelet cyclo-oxygenase and thereby prevents conversion of arachidonate 
to cyclic endoperoxides, hence blocking thromboxane A2 synthesis. This process 
differs from thrombin induced aggregation of platelets which is unaffected by 
aspirin. Therefore, inhibition of thrombin is expected both to reduce platelet 
aggregation and activation of the coagulation cascade, thereby adding to the effect 
of aspirin on the dynamic process of coronary thrombosis. Otherwise, elevated 
factor VII coagulant activity, VUc, has been associated with the risk of ischemic 
heart disease.1O It is in particular this procoagulant clotting factor which activity is 
most rapidly and extensively reduced by coumarin derivatives. On theoretical 
grounds, oral anticoagulants would have the additional advantage of decreasing the 
thrombin-mediated platelet aggregation and the generation of factor VUc, thereby 
boosting the antithrombotic profylaxis with aspirin. Based on the current knowledge 
of the pathogenesis of coronary thrombosis, combination of both anticoagulant and 
antiplatelet drugs seems an rational approach for further reduction of thrombo-
embolic complications after myocardial infarction. Since combination of full dose 
anticoagulant treatment (with target INR 2.8-4.8) and antiplatelet medication is 
associated with an unacceptable risk of bleeding,",12 combination of a low dose of 
either drug appears an appealing route for further research. Some studies have 
already suggested that the combination of both antithrombotic drugs may have a 
synergistic effect. 13.14 Recent data have also confirmed that a combination of low-
dose aspirin and coumarin may not increase the risk of bleeding." and that the 
combination of aspirin and low intensity anticoagulation may further reduce 
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recurrent events in the early phase of acute ischaemia compared to aspirin alone. 16 
However, the magnitude of the clinical effect and the incidence of bleeding 
complications of a long-term low-dose combination of both drugs after acute 
ischaemic heart disease are yet unknown. We therefore stress the need for further 
clinical trials that compare antiplatelet strategy with anticoagulant treatment and the 
combination of low intensity oral anticoagulant and low dose aspirin treatment. 
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SUMMARY 
This thesis describes the results of studies that have been initiated to assess the 
effects of long-term oral anticoagulant therapy in hospital survivors of myocardial 
infarction. 
Chapter 1 supplies a short introduction to the process of atherosclerosis which may 
lead to coronary thrombosis following rupture of a plaque. Prevention of thrombo-
tic complications by inhibition of the activated coagulation cascade by coumarin 
derivatives forms the rational for the ASPECT trial. In chapter 2 the results with 
respect to the main endpoints of the ASPECT trial are described. Oral 
anticoagulant therapy with an INR of 2,8-4,8 was given to 1,700 patients following 
discharge after acute myocardial infarction and compared to 1,704 patients taking 
placebo medication during a mean period of three years. A 10% reduction [95 % CI 
-11% to 27%] in mortality was observed, a 53% reduction [41% to 62%] in 
recurrent myocardial infarction and a 40 % reduction [10 % to 60 %] in stroke in 
patients assigned to anticoagulant therapy compared to placebo. Serious bleeding 
complications occurred fourfold more [95 % CI 2,3-6,4] frequently in 
anticoagulated patients. In chapter 3 the efficacy of oral anticoagulant treatment in 
subgroups is described. Subgroups were formed according to age, gender, 
smoking, diabetes, hypertension, previous MI, heart failure during admission, 
anterior MI, thrombolysis and beta-blockers. The relative reduction of clinical 
events by long-term oral anticoagulant treatment did not differ significantly 
amongst subgroups although the reduction in vascular events appeared lower in 
women and diabetics. On the other hand, higher age, prior myocardial infarction 
and thrombolytic therapy were associated with a higher incidence of cardiovascular 
complications whereas beta-blockers were associated with lower mortality. Chapter 
4 describes the compilation of evidence on the efficacy of oral anticoagulant 
therapy to reduce death, recurrent myocardial infarction and stroke in patients after 
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myocardial infarction. In a cumulative meta-analysis it is demonstrated that the use 
of long-term oral anticoagulant treatment in hospital survivors led to a significantly 
10% [95% CI 1 % to 19%] reduction in mortality, a 43% [36% to 50%] reduction 
in recurrent myocardial infarction and a 45 % [35 % to 60 %] reduction in stroke. 
The results described in chapter 5 indicate that participants in the ASPECT trial 
were younger, more often of male gender and used less frequently diuretics and 
ACE inhibitors compared to eligible but not randomised non-participants. Some of 
these variables are indicators of left ventricular dysfunction, suggesting that eligible 
non-participants generally had a worse left ventricular function compared to 
participants of the ASPECT trial. Older age, previous myocardial infarction and 
the use of diuretics were independent predictors of mortality in our patients. 
Thrombolytics and beta-blockers were associated with a lower mortality. 
Participation showed no association with mortality. Stratification according to the 
use of diuretics and age almost neutralized the difference in mortality between 
participants and non-participants. It is therefore concluded that the difference in 
prognosis between participants and non-participants may have resulted from 
disparity in these prognostic factors. Chapter 6 presents the estimated costs of 
anticoagulant treatment and hospitalization in anticoagulated patients versus costs of 
hospitalization in placebo patients. It is demonstrated that the costs associated with 
long-term oral anticoagulant treatment are outweighed by the reduction in medical 
costs of anticoagulated patients. We therefore concluded that long-term oral 
anticoagulant treatment is cost-effective compared to placebo in the early years 
after myocardial infarction. 
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Sam en vatting 
Dit proefschrift geeft de resultaten van het 'Anticoagulants in the Secondary 
Prevention of Events in Coronary Thrombosis' (ASPECT) onderzoek weer, dat is 
uitgevoerd om meer duidelijkheid te verkrijgen over het effect van langdurig 
voortgezette orale antistollingsbehandeling bij patienten die een hartinfarct hebben 
doorgemaakt. 
Hoofdsluk 1 geeft een beschrijving van het proces van atherosc1erose dat in een 
gevorderd stadium aanleiding kan geven tot trombosevorming in een kransslagader 
gevolgd door een hartinfarct. Tevens wordt in het licht van de ontstaanswijze van 
het hartinfarct ingegaan op het mogelijk nUtlige effect van antistollings behandeling 
hetgeen aanleiding was voor het uitvoeren van het ASPECT-onderzoek. 
In HoofdslUk 2 worden de be1angrijkste resultaten van het ASPECT-anderzaek 
beschreven. Bij 1700 patienten werd na gemiddeld 4 dagen na ontslag uit het 
ziekenilUis begonnen met antistollingsbehandeling bij een trombosedienst. Deze 
patienten zijn vergeleken met 1704 patienten die werden behandeld met placebo. 
Patienten die deelnamen aan het anderzoek hadden in vergelijking met recente, 
eerdere onderzoeken betrekkelijk weinig prognostisch angunstige parameters. Na 
een gemiddelde deelnameduur van ruim drie jaar was de sterfte bij patienten die 
een antistallingsmiddel gebruikten 10% lager [95 % Betrouwbaarheids Interval -II 
tat 27 %], het optreden van een hartinfarct 53 % [95 % BI 41 tot 62 %] en van een 
CVA 40% [95% BI 10 tot 60%] in vergelijking met patienten die placebo 
gebruikten. Ernstige bloedingscomplicaties traden echter vier maal vaker [95 % BI 
2,3 tot 6,4] op bij patienten die antistolling gebruikten. 
In Hoofdsluk 3 wordt het effect beschreven van antistollingsbehandeling in 
verscheidene subgroepen patienten. SlIbgroepen van patienten werden gevormd aan 
de hand van leeftijd, geslacht, hoge bloeddruk, eerder hartinfarct, roken, diabetes, 
hartfalen, voorwand hartinfarct, trombalyse en Jl-blokkers. Uit de analyse bleek dat 
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het effect van antistollingsbehandeling op de vermindering van het aantal 
cardiovasculaire complicaties in de verschillende groepen patienten in het algemeen 
vergelijkbaar was. Een niet significant geringer effect van antistollingsbehandeling 
op het optreden van vasculaire gebeurtenissen werd gezien bij diabetiei en 
vrouwen. Leeftijd, een eerder hartinfarct en het gebruik van trombolytica bleken 
geassoeieerd met het vaker optreden van cardiovasculaire complicaties na ontslag 
uit het ziekenhuis. Het gebruik van ll-blokkers bleek daarentegen de kans op sterfte 
te verlagen. 
In Hoofdstuk 4 wordt aan de hand van een zogenaamde cumulatieve meta-analyse 
getracht de resuItaten van eerdere onderzoeken naar het effect van langdurige 
antistollings behandeling na een hartinfarct te bundelen. Bij deze analyse b1eek dat 
een significante reductie in sterfte van 10% [95% BI I tot 19%], een reductie in 
reeidief hartinfarcten van 43% [95% BI 36 tot 50%] en in CVA's van 45% [95% 
BI 35 tot 60%] werd bereikt indien de resuItaten van de gerandomiseerde onder-
zoeken werden samengevoegd. 
Vit de resultaten van een onderzoek dat wordt beschreven in Hoofdstuk 5 bleek dat 
in de groep van patienten die voldeden aan de insluitingscriteria, maar om on-
bekende redenen niet deelnamen aan het onderzoek meer ouderen en vrouwen 
voorkwamen en dat meer patienten diuretica en ACE-remmel's gebruikten in 
vergelijking met patienten die wei aan het ASPECT -onderzoek deelnamen. Enkele 
van deze parameters zijn indirecte indicatoren van een slechtere hartwerking. 
Leeftijd, het gebruik van diuretica, diabetes en een eerder hartinfarct bleken geas-
soeieerd te zijn met een verhoogde sterftekans terwijl trombolytica en ll-blokkers 
geassocieerd bleken met een verlaagde kans op sterfte. Deelname aan het onder-
zoek bleek niet gerelateerd met sterfte. Na indeling van deelnemers en niet-
deelnemers aan de hand van leeftijd en het gebruik van diuretica bleek het verschi! 
in sterfte tussen beide groepen patienten sterk verminderd. Hieruit werd 
geconc1udeerd dat het verschi! in sterfte tussen deelnemers en niet-deelnemers 
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waarschijnlijk het gevolg was van het verschil in de aanwezigheid van prognostisch 
ongunstige cardiovasculaire factoren. 
In HoofdsllIk 6 worden de kosten gescllat van de antistollingsbehandeling en de 
ziekenhuis opnamen met daaraan gerelateerde cardiologische ingrepen bij patienten 
die antis tolling gebruikten en vergeleken met de medische kosten van ziekenhuisop-
namen van patienten die placebo gebruikten. De totale kosten van medische 
behandeling, inclusief de antistollingsbehandeling, van antistollingspatienten waren 
lager dan de kosten welke de behandeling van placebopatienten met zich 
meebracht. Dit was voornamelijk het gevolg van minder opnamen wegens hartin-
farct en instabiele angina pectoris (hartleramp). Wei hadden antistollings patienten 
iets meer kosten als gevolg van het optreden van bloeding. Deze uitkomsten geven 
aan dat langdurige antistollingsbehandeling gedurende de eerste jaren na een 
hartinfarct kosten-effectief is. 
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Hoewel de totstandkoming van vrijwel ieder academisch proefschrif! het werk is 
van velen, geldt dit in het bijzollder voor grootschalig klinisch onderzoek zoals het 
ASPECT-onderzoek. Oraag wi! ik iedereen bedanken die aan het ASPECT-
onderzoek heef! meegewerkt. Dit geldt bij uitstek de deelnemende patienten die na 
een ingrijpende medische gebeurtenis toch de moed toonden mee te werken aan een 
onderzoek waarbij ze gedurende een aantal jaren onwetend waren over de 
werkzaamheid van de aan hen verstrekte onderzoeksmedicatie. Ook ben ik grote 
dank verschuldigd aan aile artsen, verpleegkundigen en secretaressen van de 
deelnemende ziekenhuizen die het onderzoek mogelijk hebben gemaakt. Niet 
minder belangrijk was de fantastische medewerking die de medewerksters van de 
trombosediensten hebben verleend aan de uitvoering van het onderzoek. Hun 
enthousiaste inzet heef! niet aileen veel patienten gesteund bij de beslissing deel te 
nemen aan het onderzoek, maar heef! er ook voor gezorgd dat het voor de 
medewerksters van het coord ina tie centrum mogelijk was de medische gegevens 
van deelnemende patienten snel en volledig te achterhalen. 
Voor mijn meer persoonlijke dankwoord wi! ik graag beginnen met degene die 
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J.J.C. Jonker. Jail, zonder jouw onverwoestbare enthousiasme, optimisme en 
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me geen betere gids kunnen wensen en heb ook op het persoonlijke vlak altijd 
genoten van je plezierige karakter. 
Prof. Dr A. Hofman. Bert, jouw aanstekelijke enthollsiasme heef! mij geholpen te 
kiezen voor een grote verscheidenheid aan onderwerpen in dit proefschrif!. Je 
zakelijke doortastendheid heef! ervoor gezorgd dat deze opzet geslaagd is. 
Prof. Dr F.W.A. Verheugt. Freek, Hoewel je door de geografische barriere 
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gevoelsmatig altijd zeer dichtbij. 
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van onschatbare waarde geweest. Je rust, taalgevoe! en klinisch-epidemiologische 
ervaring hebben mij over menig dood punt heen geholpen. 
Ir. R.T. van Domburg. ROil, je bent verantwoordelijk voor de meeste van de 
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je altijd wei tijd vrij te maken om, met naar het scheen speels gemak, de getallen te 
kraken en toe te lichten, waarvoor mijn grote dank. 
Prof. Dr J.G.P. Tijssen. Jail, als prominent lid van de stuurgroep en schrijversco-
nuuissie had je een groot aandeel in de preparatie van het hoofdartikel. Ik wil je 
bedanken voor de soms stevige discussies die mij in staat hebben gesteld de 
hoofdresultaten van het onderzoek betel' te beschrijven. 
Prof. Dr J. van der Meer. Beste Jail, ollZe contacten waren spaarzaam maar altijd 
van groot belang voor het onderzoek. Je weloverwogen en consistente houding in 
dit onderzoek heeft vee! indruk op mij gemaakt. 
Met veel plezier denk ik terug aan de samenwerking met Terry Smith, Anja de 
Jong, Dorine van del' Veen, Petra Eigenraam, Ingrid Kensenhuis, Christa Mahler, 
Adriana van der Sman, Gien Visser, Liesbeth Wielders, Desiree van den Berg en 
Ada Dijkhoorn, die het ASPECT-coiirdinatiecentrum hebben 'bemand' tijdens de 
uitvoering van het onderzoek. Zonder jullie geweldige werklust en doorzet-
tingsvermogen zou het onderzoek nooit geslaagd zijn. 
Dr A.J. Azar. Beste Aida, hartelijk dank voor de vele jaren dat je de databank van 
ASPECT hebt "gemanaged". 
De leden van de stuurgroep wil ik hartelijk bedanken voor de jaren van steun die 
zij hebben betoond. Graag wil ik uiting geven aan mijn dankbaarheid voor jullie 
betrokkenheid en enthousiasme bij de uitvoering van het onderzoek. 
Tineke Gerrits, Odette Paauwe, Karin Bloemkolk en het Bestuur van de Federatie 
van Nederlandse Trombosediensten dank ik voor de vele jaren van hulp en steun. 
Odette en Karin, jullie wil ik nadrukkelijk bedanken voor de persoonlijke betrok-
kenheid tijdens de uitvoering van het onderzoek. 
P.H van del' Burgh (Pieter), P. Molhoek (peter), Dr C. van Rees (Cees), Dr P. 
128 
Sam ell vatting 
Koudstaal (Peter), Dr A. Wintzen (Axel) en Dr G. den Ottolander (Gerard), als 
leden van de Mortality and Morbidity Classification Committee zijn we regelmatig 
bijeengekomen om op jullie vakgebied met een combinatie van doortastendheid en 
gezond verstand de ziekenhuisopnamen op juiste wijze te beoordelen. Ik wi! jullie 
danken voor de onbaatzuchtige wijze waarop jullie al de jaren aan dit onderzoek 
mee hebben gewerkt. Wijlen Prof. J. van der Graaf heef! als lid van deze commis-
sie ook een belangrijke bijdrage geleverd aan het onderzoek. 
Tenslotte wi! ik de medewerkers van de thrombosedienst Rotterdam (STAR), de 
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